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VESTIGIAL-LIKE 1 IS A SHARED TARGETABLE CANCER-PLACENTA ANTIGEN 
EXPRESSED BY PANCREATIC AND BASAL-LIKE BREAST CANCERS 
 
Sherille Denaé Bradley, M.Sc. 
Advisory Professor: Gregory A. Lizee, Ph.D. 
Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for 
inducing clinical regression by targeting tumor-associated antigens (TAA). To expand the TAA 
landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass 
spectrometry analysis of HLA class I-bound peptides from tumors of PDAC patients. This led to 
the identification of a shared HLA-A*0101 restricted peptide derived from co-transcriptional 
activator Vestigial-like 1 (VGLL1), a novel putative TAA demonstrating overexpression in 
multiple tumor types and low or absent transcript expression in normal tissues with the exception 
of placenta. VGLL1-specific CTL isolated and expanded from the blood of a male PDAC patient 
showed the capacity to recognize and kill in an antigen-specific manner a majority of HLA-
A*0101 allogeneic tumor cell lines derived not only from PDAC, but also ovarian, bladder, 
gastric, lung and basal-like breast cancers. Gene expression profiling revealed that VGLL1 is a 
member of a unique group of cancer-placenta antigens (CPA) that may constitute safe 
immunotherapeutic TAA targets for patients with multiple different cancer types. Additionally, 
we demonstrate that VGLL1 is associated with poorer patient survival rates in pancreatic cancer. 
However, its role in cancer remains largely uncharacterized. VGLL1 shares a similar binding 
motif to the TEAD family of genes with the oncogenes, YAP/TAZ that promote malignancies 
through the Hippo signaling pathway. We show that VGLL1 may play a significant role in 
tumorigenesis by inducing tumor cell proliferation, migration, and invasion.  
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1.1 Introduction to Immunology 
Immunology is the study of the immune system and its role in protecting the body 
against foreign pathogens and disease [1, 2]. The immune system is comprised of two 
main subcategories of immunity, innate and adaptive immunity [2, 3]. Innate immunity is 
the body’s first line of defense against foreign entities [4, 5].  The innate response is 
immediate non-specific protection made to fight against invading bacteria, viruses, and 
fungus [3]. Adaptive immunity, also referred to as specific or acquired immunity, is 
created in response to the body’s exposure to these foreign substances over time [6].  
Adaptive immunity can be further subdivided into humoral and cell-mediated immunity 
[3, 6].  Humoral immunity is regulated by activated B cells through the production of 
antibodies, while cell-mediated immunity is carried out by T-lymphocytes cells (T cells). 
There are three major categories of T cells: helper, regulatory, and cytotoxic [2]. Within 
each of these three categories, there are multiple T cell subtypes. Helper T cells are 
primarily CD4+ T cells.  Helper T cells produce molecules called cytokines that signal to 
other immune cells in response to pathogens that the T cell recognizes. In contrast, 
regulatory T cells (T regs) play a role in the suppression of the immune system. T regs 
function to protect against the immune system by acting as a shut-off switch when it is no 
longer needed [2, 7]. Lastly, cytotoxic T cells (CTLs or CD8+ T cells) are the primary 
effector cells of the immune response. CD8+ T cells produce molecules that destroy 
foreign pathogens or infected cells once activated.  
The power of the immune system can be harnessed to target not just invading 
microbes and viruses, but it can also be used as a biologic therapy for the treatment of 
cancer. While both the innate and adaptive immune system can be used as therapeutic 
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interventions of cancer, the adaptive immune response plays a vital role in anti-tumor 
immunity.  As we will discuss further, this is because CTLs are the critical regulators of 
the cell-mediated immune response against cancer cells. In the following section, we will 
briefly discuss the history of immunotherapy, its various forms, and multiple ways that 
the adaptive immune response can be harnessed to treat cancer. 
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1.2 Immunotherapy 
Immunotherapy aims to induce anti-tumor responses by augmenting immune 
surveillance and overcoming mechanisms of immune suppression. In recent years, 
immunotherapy has emerged as a viable treatment option for multiple cancers. However, 
immunotherapy wasn’t used routinely for many years after its initial discovery due to a lack 
of  known mechanisms of action and poor reproducibility [8] [9]. The first attempts to 
harness the immune system for the treatment of cancer started in the 1890s by William B. 
Coley. Coley observed disease remission in patients who were injected with mixtures of live 
and attenuated bacteria [10, 11]. Since Coley didn’t know the mechanism of action, and 
studies yielded mixed results, immunotherapy remained dormant for many years after this 
initial observation (Figure. 1.1). In the late 1950s, Thomas and Burnet played a major role in 
bringing immunology to the forefront. They proposed that lymphocytes were mediators of 
immunosurveillance by identifying and eliminating somatic cells transformed through 
mutations. However, it wasn’t until the 1970s, that Carswell et al., discovered that the 
eradication of tumors was a result of tumor necrosis factor production in response to the 
bacterial endotoxins [12].  Morales et al. went on to publish their findings in the 1970s 
showing, that Bacillus Calmette-Guerin (BCG) could be used to treat bladder cancer [13]. At 
this point, immunology was began to be taken seriously as a treatment option [13]. Since 
then, many further advances in cancer immunotherapy have led to remarkable improvements 
in response rates, progression-free survival, and overall survival in patients.  
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Figure 1.1 History of Tumor Immunology.	
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Figure 1.1 The History of Tumor Immunology. A timeline of the origins of tumor 
immunology. The timeline includes some of the major accomplishments and discoveries 
since its beginnings that has led to advancements in immunotherapy.  
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There are several forms of immunotherapy that fall into one of two categories: passive 
immunotherapy and active immunotherapy [14]. Active immunotherapies can be non-
specific or specific. Active immunotherapies directly induce an immune response through the 
eliciting the host’s endogenous immune system to fight disease [9, 14]. Passive 
immunotherapy differs in that it relies on elements constructed in the laboratory, which are 
then administered to patients to provide exogenous immunity [15, 16]. Cytokines and 
chemokines, such as interleukin-2 (IL-2) and interferon-alpha (IFN-α), are two common 
forms of active immunotherapy (Table 1.1) [17, 18]. They can be used to boost the immune 
response and lead to increased proliferation of tumor-eliminating T cells and or activation of 
disease-fighting cells [17, 19]. Vaccines are another biological agent used to induce anti-
tumor responses. These can include peptide, viral, and dendritic cell-based vaccines [20, 21].  
One form of passive immunotherapy involves the transfer of monoclonal antibodies into 
patients to target an array of specific antigen targets [22]. Monoclonal antibodies can bind to 
surface targets on cancer cells and act as downstream signaling pathway blockers of 
proliferation [22]. For example, bevacizumab (Avastin) is an FDA-approved monoclonal 
antibody against the growth factor VEGF-A (Table 1.1). However, there are also monoclonal 
antibodies that can also be used to inhibit receptors that normally act to halt the immune 
response. Examples of such inhibitors are checkpoint blockade therapies, or immune 
checkpoint modulators. These antibodies bind to the surface receptors on T cells that 
effectively “put the brakes” on T cell activation, blocking them and allowing them to 
continue to be active and attack the tumor [23]. Most recently, the Nobel Prize for 
Physiology and Medicine was awarded to, Dr. Jim Allison and his colleague Dr. Tasuku 
Honjo, for their groundbreaking discovery of cytotoxic T-lymphocyte-associated protein 4 
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(CTLA-4) checkpoint  molecules and programmed death (PD-1) respectively [24]. Their 
discoveries are perhaps one of the most prominent findings in the last ten years and has 
radically impacted the treatment of metastatic melanoma [25, 26]. 
No matter the type of immunotherapy used, the key to specific anti-tumor immunity lies 
within the target. One of the most vital categories of targets of  anti-tumor immune responses 
are tumor-associated antigens (TAAs). These tumor-specific targets are recognized by T cells 
to induce an immune response for tumor elimination [27]. Tumor-associated antigens are 
peptides found on the surface of tumors bound to Human Leukocyte Antigens (HLA) 
molecules (Figure 1.2). TAAs come in a variety of forms including, glycolpeptides, viral or 
bacterial derived-peptides, and phosphopeptides [28]. TAAs can be targeted with multiple 
therapeutic options, including cancer vaccines and T cell-based immunotherapies [28].   
 
 
 
 
 
 
 
 
 
	
	 	 	
	
9	
	
                  
 
 
 
 
 
 
 
 
Table 1.1 Forms of Immunotherapy.	
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Table 1.1 Forms of Immunotherapy. A table displaying current active and passive 
immunotherapeutic approaches. 
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1.3 Tumor Associated Antigens 
The discovery of tumor-associated antigens in the late 1950s revolutionized our 
understanding of tumor immunology. Dr. Richmond T. Prehn’s research showed in mice 
that an immune response could be mounted against a carcinogen-induced sarcoma that 
later protected the mice against future challenges with the same tumor  [29] [30]. His 
work provided evidence that tumors contained specific target antigens that could induce 
immunity and lasting immune memory [30]. These studies were the foundation for work 
that has continued to identify human tumor antigen targets. It is known that tumor 
antigens can be derived from self-proteins that are either over-expressed, tissue-specific, 
or arise due to mutations [27].  Tumor-associated antigen targets must possess some level 
of immunogenicity with low immune tolerance in order to be effective targets of CTL-
mediated immune responses. Figure 1.2 demonstrates a “gradient” of tumor- associated 
antigens ranging from non-targetable self-antigens (high tolerance, low immunogenicity) 
to antigens (low tolerance, high immunogenicity). 
Although most self-antigens are not targetable due to unacceptable toxicity against 
normal tissues, there are classes of self-antigens that are potentially targetable [31]. Some 
antigens are expressed in specific normal tissues despite being found abundantly in 
tumors; these are known as tissue differentiation antigens [31]. One example of a tissue 
differentiation antigen is the protein enzyme tyrosinase. It is expressed only by 
melanomas and by normal skin cells known as melanocytes [32]. Another class of self-
antigens are cancer-testis antigens (CTAs); these include antigens such as MAGE-A and 
NY-ESO-1 [33-35]. As the name suggests, they are found in high abundance primarily in 
testis tissue and in some tumors. Over-expressed tumor-associated antigens are found in 
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low abundance in multiple normal tissues but are highly over-expressed in tumors. The 
protein HER2 is an example of an antigen that is expressed by normal tissues but is 
highly overexpressed in multiple cancers, such as breast, gastric, and lung cancers [36]. 
Neo-antigens are highly tumor-specific antigens that arise from somatic tumor-
associated mutations. 
These targets are highly sought are the most sought after because of their unique 
tumor-specific sequences avoid issues of T cell tolerance and auto-reactivity [37]. 
Mutated TAAs can originate from frameshifts, deletions, insertions, fusions, and or other 
structural rearrangements of proteins [38]. Additionally, oncogenic viruses, such as 
human papillomavirus (HPV), can also induce the expression of unique tumor-specific 
antigens, which can be exploited as tumor-specific targets [39, 40].  
Continued efforts to identify targetable tumor antigens shared by large numbers of 
cancer patients remain vital to the current and future success of T cell based cancer 
immunotherapies. 
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Schematic	of	tumor	associated	antigens		
 
 
 
 
 
 
Figure 1.2 Schematic showing different categories of tumor associated antigens gradient.	
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Figure 1.2 Schematic showing different categories of tumor associated antigens gradient. 
Tumor cell representing the several tumor associated antigens found on its surface. The 
figure demonstrates the range from non-mutated (high tolerance, low immunogenicity) to 
foreign (low tolerance, high immunogenicity) antigens. 
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The discovery of TAAs has led to the development of multiple cancer 
immunotherapies, including peptide vaccines and adoptive T cell therapies. For example, 
cancer vaccines utilize tumor-associated peptides to prime antigen-specific T-cell responses 
in the body and increase the numbers of TAA-specific CTLs. Adoptive T cell therapy 
involves the isolation and ex-vivo expansion of tumor-reactive T cells. The benefit that 
adoptive T cell therapy has over vaccines is the ability to expand T cells to a greater extent, 
then what vaccines alone can accomplish.  
Lymphocytes that infiltrate into the stroma of tumor nodules are referred to as tumor- 
infiltrating lymphocytes (TILs) [41, 42]. TILs provided the first evidence that the immune 
system can recognize tumor antigens [43, 44]. In 1988, Wolfel et al. showed that target 
structures presented by HLA molecules on tumor cells could induce the killing of these cells 
by CTLs [44]. The target structures identified were later described as the first tumor antigens 
recognized by T cells [45]. Intracellular proteins are comprised of polypeptide chains, and 
within a cell, they are degraded into shorter peptides that can be presented at the cell surface 
when loaded onto HLA-I molecules.  HLA class I-bound peptides usually range  in size from 
8 to 12 amino-acids, and are derived from most cell-associated proteins and are recognized 
by the T-cell receptor of CTLs [46].  Peptides can only bind to specific HLA alleles that 
possess particular amino acid binding motif preferences [46, 47].  The targeting of TAAs 
through T cell mediated immunity has been the foundation of modern-day .cancer 
immunotherapy. The next section will discuss the role of TAAs in CTL-mediated 
immunotherapies.  
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1.4 CTL-mediated immunotherapy  
Cancer immunotherapies have grown exponentially in recent years and have made 
remarkable improvements in patient survival.  The adaptive immune response relies heavily 
on immune effector cells known as cytotoxic t-lymphocytes. Also referred to as CD8+ T 
cells, CTLs are known to be major players in inducing the regression of tumors (Figure 
1.3B). CD8+ T cells possess T cell receptors (TCRs) that recognize HLA class I molecules 
displaying peptide antigens on all cells in the body (Figure 1.3A). In addition to 
distinguishing self-antigens from pathogen-derived antigens, effector CD8+ T cells can also 
be primed to target tumor antigens [48].   
Several different T-cell based immunotherapies have been developed to treat cancer. 
TILs are have set the foundation for the expansion of adoptive transfer of tumor reactive T 
cells.  The cytokine interleukin-2 (IL-2) is responsible for the growth, proliferation, and 
differentiation of T cells to become effector cells. T cells also produce IL-2 in recognition of 
a foreign pathogen or a tumor antigen. Dr. Steven Rosenberg found that IL-2 as a 
monotherapy was an effective treatment option for metastatic melanoma patients [49, 50]. He 
also demonstrated that TILs extracted from melanoma tumors could be expanded ex vivo 
with the administration of high dose IL-2 in vitro [51, 52]. IL-2 given as either a 
monotherapy or in combination with TILs were some of the first successful  T-cell mediated 
immunotherapies developed for the treatment of cancers [41, 52].   
An alternative form of adoptive T cell therapy involves the isolation and expansion of 
endogenous tumor-antigen specific T cells (ETCs) from peripheral blood [50]. ETC 
treatment uses the peripheral blood as a source for the isolation of low-frequency, tumor-
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reactive T cells [50, 53]. Much like TILs, these T cells can be isolated, stimulated, and 
expanded ex vivo to high quantities, then re-administered to cancer patients as a robust form 
of therapy [54]. In TIL therapy the specific tumor antigen target is usually unknown at the 
time of treatment; thus TIL therapy is usually a highly personalized treatment [55]. ETC 
targets specific, known tumor targets and has the potential to be a shared immunotherapy that 
can benefit many patients [50]. 
Tumor antigen peptides can be used to prime tumor antigen-specific T cells in vitro. 
Cells also found in the peripheral blood, known as antigen-presenting cells (APCs), primarily 
dedritic cells, monocytes, and B lymphocytes are used to activate antigen-specific T cells and 
induce proliferation  [20, 55]. After in vitro stimulation with peptide-pulsed APCs, antigen-
specific T cells expand to billions of cells and used for therapeutic purposes [53].  Once a 
tumor-antigen specific T cell deemed to have good anti-tumor activity, the therapeutic TCR 
can be cloned and used for TCR engineering, a relatively new treatment [56]. 
TCRs  that have the high affinity for their tumor antigen target can be cloned and 
transduced into T cells that normally cannot recognize the target antigen [57]. These 
engineered TCR-T cells can be administered to other patients who share the same antigen 
target of interest, as well as the presenting HLA molecule. TCR-T based immunotherapy 
likely has the potential to reach a much broader patient population. 
The first clinical trials using T cell therapies were done in the setting of metastatic 
melanomas [50, 58]. Targeting the tumor antigens, MART-1 and gp100, has shown good 
clinical activity with TIL and ETC [53, 57]. Some of which have induced complete 
responders or induced dramatic regressions in tumors [53, 58]. Although, there has been 
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minimal toxicity noted in these patients, TCR-T therapies against these same antigens have 
induced unacceptable toxicities, by killing normal melanocytes. Although antigen-specific 
immunotherapies are available for melanoma, many other tumor types have no known TAA, 
to target, which represents an important unmet need in the field. 
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Figure 1.3. T cells recognize antigens bound to and presented by HLA class I molecules.	
Antigen	presentation	and	T	cell	Recognition	
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Figure 1.3. T cells recognize antigens bound to and presented by HLA class I molecules. 
A) Crystal structure of an HLA class I molecule displaying where peptide antigens are 
bound. B) HLA class I molecule presenting an unknown tumor antigen to a T cell for 
recognition and killing of the tumor.  
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1.5 The role of HLA class I molecules in CTL-mediated immune responses 
HLA molecules constitute the central focus of the T cell mediated immune response. 
HLA class I molecules display peptides display peptides expressed by all nucleated cells of 
the body, including self, non-self, pathogen, and tumor-derived to effector T cells. All cells 
can present endogenously derived peptides on HLA class I molecules. Specialized APC’s, 
such as DC’s can also display exogenously-derived peptides in a process called cross-
presentation. Mature  HLA class I complexes are assembled in the endoplasmic reticulum 
(ER); they are heterodimers assembled from a polymorphic heavy chain, a light chain called 
β2- microglobulin (β2m) and an antigenic peptide (Figure 1.4) [59, 60]. Proteasomes 
degrade cytoplasmic proteins into smaller peptides, which are transported into the ER by the 
transporter associated with antigen presentation (TAP) and are loaded into the peptide-
binding grooves of the HLA-I molecules. The HLA-I binding groove accommodates peptides 
8 to 12 amino acids in length [59]. In the ER, HLA-I molecules are stabilized by chaperone 
proteins such as calreticulin [61]; in addition, the molecule tapasin interacts with TAP to 
assist in the delivery of peptides to HLA-I molecules. When a peptide is successfully bound 
to HLA-I  heavy chain and β2- microglobulin as a trimolecular complex, it exits the ER via 
the secretory pathway and travels to the cell surface in vesicles for presentation (Figure 1.4). 
Since HLA-I display these peptides at the cell surface, and then they play an essential role in 
antigen presentation and T cell surveillance. 
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Figure 1.4 HLA Class I processing and antigen presentation pathway.  	
	
	 	 	
	
23	
	
 
Figure 1.4 HLA class I processing and antigen presentation pathway.  Endogenously 
derived proteins are degraded, loaded on to HLA molecules, and shuttled to the cell surface 
for presentation. HLA molecules can fit specific antigens in their binding groove and present 
to T cells on the surface of cells.  
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Human CTLs recognize the products of the three classical genes; HLA-A, HLA-B, 
and HLA-C. Each HLA type can recognize and bind uniquely to many different peptides 
dictated by the molecular properties of the their peptide binding grooves (Figure 1.4) [62]. 
HLA-A and HLA-B are expressed at higher surface levels in human cells than HLA-C. The 
extremely high level of HLA polymorphism results in different peptide-binding grooves that 
recognize and bind characteristic peptide sequences, allowing for each individual to present a 
wide and distinct array of peptides.  
Each HLA-I molecule loaded with peptide is expressed on the cell surface to present 
peptides to CD8+ T cells. This can induce clonal expansion of effector of T cells, target cell 
killing, or cytokine release, depending on the APC and T-cell differentiation state. Each T 
cell contains a unique T-cell receptor that binds to HLA-I/peptide complexes; when this 
occurs, many more stabilizing receptors bind to one another from each cell, thus allowing the 
T-cell to stay in close contact with the APC. This induces the release of effector molecules 
such as Granzyme B and perforin by CD8+ cytotoxic T cells to induce target cell death. 
Granzyme B is a serine protease and perforin is a pore-forming protein that facilitates it’s 
entry into target cells; once inside, it triggers an increase of intracellular calcium that 
eventually leads to the apoptosis of target cells [61, 63]. 
The antigenic landscape of tumors, or immunopeptidome, is the collection of the 
peptides are presented by HLA molecules [64]. By analyzing the immunopeptidome of 
cancers, researchers have discovered novel TAA targets to facilitate the treatment of cancer. 
Multiple methods have been used for tumor antigen discovery, but in recent years mass 
spectrometry analysis has proven the most useful for high-throughput.The following section, 
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will discuss how mass spectrometry-based antigen discovery has made major strides in 
cancer immunotherapy. 
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1.6 Mass spectrometry-based antigen discovery 
In recent years, there have been significant improvements in the field of proteomics, 
the large-scale study of proteins. Coupled with technological advances in genomics, 
bioinformatics, and prediction platforms, these tools have greatly facilitated 
immunopeptidome discovery [64]. For many years, the most commonly used method for 
tumor antigen discovery was in-silico based [65]. The use of computer programs and 
prediction software has been the primary methodology for HLA-I binding prediction, but 
these methods as a single form of identification have several limitations.  
In-silico approaches to identify tumor antigens rely on peptide sequences that have 
been eluted from different HLA alleles [66], [65].  Together with binding affinity algorithms 
that are derived from in-vitro binding assays, these tools are capable of predicting potential 
tumor antigen sequences that may be viable HLA-bound targets. They are also are capable of 
identifying possible neo-antigens peptides [67]. However, neo-antigen discovery is much 
more challenging and costly since it requires massive amounts of DNA and RNA sequencing 
data from both normal and tumor tissues that must be analyzed for non-synonymous 
mutations [64, 68]. These mutated protein variants are then translated into amino acid 
sequences in silico and analyzed with HLA peptide binding programs against all known HLA 
alleles [68]. Examples of these programs include NetMHC or EpitoolKit. If potential 
antigens are identified, synthetic neo-antigens can be used to conduct T cell screening assays 
for potential reactivity [68, 69].  
Mass spectrometry (MS) can be used as a more direct form of tumor antigen 
discovery that is both unbiased and comprehensively investigates the entire peptide repertoire 
of a given tumor sample [64]. This sample may be a solid tumor specimen, cell line, or even 
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bodily fluids. The current process of MS-based antigen discovery starts with 
immunoprecipitation (IP) of HLA class I complexes from solubilized lysates [64]. IP’s are 
typically conducted with pan-HLA class I or pan-HLA class II antibodies [68]. However, 
HLA-allele specific antibodies can also be used as well. The peptides are eluted in low PH 
and are separated by high-pressure liquid chromatography and injected into a mass 
spectrometer for analysis [68]. The results are searched against publicly-available  protein 
databases, using serch tools such as Mascot or MaxQuant [70].  
One of the benefits of MS over in-silico methods is the high-throughput [64]. 
Depending on the size of sample, up to thousands of potential tumor antigen targets can be 
detected in less than 2 hours. Additionally, targeted-MS, a process that adds a higher level of 
fractionation of the sample, can increase the depth at which the sample is analyzed and 
provide greater sensitivity. Targeted-MS enables more accuracy and reproducibility for 
specific peptides of interest [71, 72]. Typically, target-MS is used as a secondary method 
after a sample has been analyzed in discovery mode. Thus, it is more suited for peptide 
validation, rather than discovery. 
There are several databases that are used to help to determine the targetability of MS-
eluted peptides. The Swiss-Prot is a database that complies the information from scientific 
literature and computational analyzes on human protein sequences [73, 74]. The database is 
used to search for MS-eluted peptides to provide any relevant information on proteins. 
Additional validation and vetting of MS-eluted peptides can be determined by evaluating the 
expression of peptide-encoding genes in primary tissues and tumors. Normal tissue transcript 
expression determined by RNA sequencing is found in the Genotype-Tissue expression 
(GTEx) Portal database.  Overall patient tumor tissue expression  is available in the The 
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Cancer Genome Atlas (TCGA) database. TAAs found to be highly expressed in normal 
tissues according to the GTEx are immediately eliminated as potential therapeutic targets.  
While, TAAs that are highly over-expressed in tumors with low expression in normal tissues 
can be further evaluated. HLA-I peptide prediction binding algorithm databases are also used 
to add another level of confidence that eluted peptides are presented on the surface of the 
tumor. These HLA-I algorithms provide information on the predicted binding affinity of each 
peptide, indicating if the peptide weakly or strongly binds to HLA alleles. Together, these 
databases allow for in-depth analysis of MS-eluted peptides to determine if they are suitable 
therapeutic targets. 
Currently, MS-based antigen discovery has expanded the immunopeptidome 
landscape many tumor types, including melanoma, hepatocellular carcinomas, leukemia, and 
renal cell carcinomas [69, 75]. It has primarily been used to discover shared antigens, but 
now researchers are also using this method to detect neo-antigens for personalized therapies 
or shared neo-antigen epitopes [76]. This method of detection is currently being developed 
for neo-antigens but has yielded some positive results in highly mutated cancers, like lung 
cancer and melanomas [77, 78]. There remain limitations to sensitivity, and these analyses 
require large sample sizes. 
MS-based antigen discovery coupled with in silico methods has helped to expand the 
targetable immunopeptidome landscape of multiple cancers. HLA prediction binding 
algorithms, in particular have served as an important validation to vet eluted peptides. 
 MS-based antigen discovery has also helped to improve HLA class I binding algorithms for 
future researchers. The development of these methods, has allowed us to analyze additional 
cancers that have historically poor response rates to the current standard of care options. 
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Cancers types such as ovarian and pancreatic cancer for example have a lack of alternative 
treatments once patients fail to respond to front line treatments. This forms the rationale for 
this dissertation work, as will be discussed future in the following section. 
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1.7 Long term goal and rationale for this dissertation 
The long-term goal of this dissertation was to develop a novel and effective cytotoxic 
T cell-based immunotherapy for cancer patients. Through this work, we aimed to identify 
shared tumor antigen targets in two cancers that have poor response rates to the current 
standard of care therapies, ovarian cancer and pancreatic cancer. Although, tumor associated 
antigen discovery is feasible for these cancers, to date there remains no T cell-based 
immunotherapeutic options for these patients. Cancer vaccines have been the primary 
objective of previous studies, but these have not provided benefits in the overall survival 
rates of these patients. There a few ongoing clinical trials using CAR T cells against a select 
few antigen targets for ovarian cancer. However, the trials are still very early, and have yet to 
show any promising results. Thus, there remains an un-met need to identify and validate 
viable tumor associated antigens in these cancers to faciliate T cell-based immunotherapies.  
We chose to focus our efforts on the identification of non-mutated, overexpressed 
antigens in ovarian and pancreatic cancer. Our goal was to identify a shared tumor-associated 
antigen with little to no expression in normal tissues. If the TAA was also shared amongst 
both or additional cancer types, that was also ideal. Finally, we took into consideration the 
diversity of the HLA types from our patient samples, aiming to find epitopes from HLA 
alleles expressed at a high frequency in the worldwide if population.  Due to our clinical 
collaborators, we had the rare opportunity to have access to fresh patient tumor samples for 
our studies. Additionally, we the expertise and knowledge on how to utilize mass-
spectrometry based tumor antigen, where we used this method to identify tumor antigen 
targets in melanoma. Using high-throughput tandem mass spectrometry, we successfully this 
method to identify the tumor associated antigen, SLC45A2 [79]. In collaboration with a 
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bioinformatics expert and our clinical collaborator, we also were able to validate the peptide 
target and then isolate low-frequency endogenous, T cells from the peripheral blood of 
healthy donors. Furthermore, we were able to show that these SLC45A2-specific T cells 
could recognize and eliminate tumors that expressed the target gene and the appropriate HLA 
types. This is now the basis for an ongoing clinical trial for uveal melanoma patients. The 
work in this dissertation applies the same antigen discovery concepts to ovarian and 
pancreatic cancers, leading to the discovery of Vestigial-like 1 (VGLL1) as a potentially 
targetable TAA for multiple tumor types. 
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1.8 Overall hypothesis and Specific Aims  
 
It was our central hypothesis that the accurate identification and selection of 
appropriate tumor associated antigens in ovarian or pancreatic cancer, would provide a 
foundation on which to develop a novel and effective T-cell based immunotherapy. In this 
dissertation we tested this hypothesis through fulfilling the following aims: 
 
AIM 1. Identify tumor-associated antigen-encoding genes from patient tumor 
specimens. 
 
Aim 1.1. Perform HLA class I-bound peptide elution and mass spec analysis of patient 
specimens to identify potential tumor-associated peptides. 
 
Aim 1.2. Select best shared tumor-associated target peptides utilizing bioinformatics 
algorithms. 
 
AIM 2. Generate antigen-specific cytotoxic T-cells against validated peptides and 
expand the shared tumor-associated target repertoire.  
 
Aim 2.1. Validate best peptide candidates and generate antigen-specific CTLs against 
selected targets. 
 
Aim 2.2. Test the specificity and cytotoxicity of generated CTLs using HLA-matched tumor 
cell lines and primary cell lines. 
 
Aim 2.3. Identify shared TAA targetable tumors by testing the generated CTLs against 
additional HLA-matched TAA-expressing tumor types. 
 
AIM 3.  Characterize the role of the identified tumor-antigen VGLL1 in cancer 
progression. 
 
Aim 3.1. Utilize siRNA and lenti-viral vectors to generate knockdown and overexpressed 
VGLL1 tumor cell lines, and analyze morphological changes in transduced tumor cells. 
 
Aim 3.2 Explore the role of VGLL1 as a promoter of cancer progression by examining 
VGLL1 over-expressing and knockdown tumor cells for proliferation, migration, and 
invasion of the tumor cells. 
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CHAPTER II: 
OVARIAN CANCER TUMOR ASSOCIATED ANTIGEN DISCOVERY  
AND T CELL GENERATION 
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2.1 Rationale for tumor antigen discovery in ovarian cancer  
Our first aim sought to delve into the immunopeptidome landscape of ovarian cancer 
(OVCA) to identify viable tumor antigen targets. Specifically, we sought to target the most 
aggressive and deadly form of OVCA, epithelial ovarian cancer (EOC) [80]. Epithelial 
ovarian cancer is the leading cause of death among gynecological cancers and has been 
coined the “silent killer” [81-83]. The current five-year survival rate for EOC patients is 
about 44%, due primarily to its metastatic nature and late-stage diagnosis [80, 83, 84]. The 
common symptoms of ovarian cancer are similar to other gastrointestinal and gynecological 
conditions and thus are often are not easily attributed to the early diagnosis of ovarian cancer 
[81, 85].   
The current standard-of-care relies on surgical tumor debulking followed by cisplatin-
based chemotherapy [86]. Despite the high rate of initial responses, acquired cisplatin 
resistance in ovarian cancer remains a significant roadblock to the successful treatment of 
patients. Currently, immunotherapy for EOC is only considered after patients have failed 
front-line therapy [81, 87]. Several clinical trials using adoptive T cell including TILs and 
CAR-T cells have been conducted or are underway.  Immune checkpoint inhibitors, anti-
VEGF, and poly (ADP-ribose) polymerase (PARP) inhibitors are also being tested clinically 
[88, 89].  
The presence of tumor-infiltrating lymphocytes (TILs) in EOC patient tumor samples 
does show an increased correlation with progression-free survival and overall patient survival 
[90]. This suggest that a T-cell based immunotherapy may potentially improve patient 
outcomes. EOC is known to have a highly immunosuppressive environment, similar to 
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pancreatic cancer [91, 92]. Therefore, EOC immunotherapies may need to be combined with 
additional anti-tumor approaches to achieve full treatment efficacy.  
  Adoptive T cell therapy approaches have been used in clinical trials for EOC [93]. 
Most notably, TIL therapy has had some mixed but mostly promising results. TILs promote 
tumor regression in patients with either advanced disease or recurrent platinum-resistant 
cancer [94]. However, toxicity remains an issue with EOC patients. As a single treatment, 
platinum-based chemotherapy is very toxic to patients [95]. In clinical trials, the combination 
of TILs and cisplatin, even without IL-2 still resulted in unfavorable toxicities [95]. 
Overall, clinical data supports the notion that the presence or absence of TILs does 
have a significant impact on response rates of patients [96]. This does bring up the question 
of what exactly are the TILs recognizing?  Additionally, how can we boost this anti-tumor 
response? Are there potentially shared target antigens present in these EOC patient tumors? 
Having a better understanding of the antigen targets presented by these tumors could improve 
the outcome for EOC patient survival.  
The next section will discuss how tandem mass spectrometry was utilized to analyze 
fresh ovarian tumor specimens derived from patients at M.D. Anderson Cancer. In 
collaboration with Dr. Amir Jazaeri in the M.D. Anderson Gynecological Oncology 
department, we analyzed over 30 ovarian tumor samples derived from patients. To identify 
tumor-associated antigens, we performed HLA class I immunoprecipitation and acid elution, 
followed by mass spectrometry analysis to identify HLA-bound peptides found within the 
tumor samples. 
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2.2. Ovarian cancer MS-based TAA discovery and antigen-specific T cell generation 
2.2a.) Identification of ovarian cancer TAAs from fresh patient tumor specimens. 
In the first aim, our goal was identifying appropriate target genes through direct proteomic 
analysis of OVCA patient tumor samples. To achieve this, we analyzed OVCA tumor 
samples from freshly excised patient biopsies obtained from our MD Anderson surgical 
collaborator Dr. Amir Jazaeri. We lysed the tumor specimens, and then performed 
immunoprecipitation of HLA class I molecules, and followed by acid elution of HLA-bound 
peptides. Next, we utilized tandem mass spectrometric analysis to identify tumor-associated 
peptide antigens, as shown in (Figure 2.1).   
In tandem mass spectrometry, individual fragmented peptides ions are displayed as a 
mass spectrum. The full length peptide backbone is fragmented into b and y ions.  The 
spectrum consists of peaks corresponding to each fragmented ions mass-to-charge (m/z) ratio 
values (Figure 2.2). Multiple copies of the same peptide can be within the sample, and the 
relative intensity of the fragmented ions is depicted on the y-axis. Higher quality spectra 
contain more of the ion fragments. The spectra  fragments are matched against Swiss-port 
databases to determine the theoretical full-length peptide identity. 
In total, we completed peptide elutions on 38 fresh OVCA tumor specimens. Nearly 
all of the samples were collected from high-grade epithetical ovarian cancer patients, with the 
exception of two patients (Table 2.1). Additionally, the site of where the tumor was collected 
varied but was mainly derived from the omentum, which is an indication of advanced disease 
and metastasis (Table 2.1).  The majority of the patients also underwent HLA typing to 
determine their HLA allelic expression, an important step in validating our MS results. This 
allows for peptide binding predictions of eluted peptides (Table 2.1).   
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Peptide	Identification	from	Fresh	Tumor	
Samples	by	Mass	Spectrometry	Analysis	
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Peptide Identification from Fresh Tumor Samples by Mass Spectrometry Analysis.   
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Figure 2.1. Peptide Identification from Fresh Tumor Samples by Mass Spectrometry 
Analysis.  Patient tumor samples containing surface bound HLA-I molecules were extracted, 
lysed, and acid washed to eluted the peptides. The eluted peptide samples were then analyzed 
by mass spectrometry analysis for the identification of peptides found within the sample. The 
peptide ions are separated by mass/charge, then the ions are fragmented, and laser then 
detects the ions. A mass spectrum is the final output for fragmented peptides detected within 
the sample.  
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MS/MS	mass	spectrum		
 
 
Figure	used	with	premission	from	author:	
Hughes, C., Ma, B., Lajoie, G.A. De novo Sequencing Methods in Proteomics. Methods Mol 
Biol. 2010;604:105-21.  
 
 
 
 
 
 
 
Figure 2.2. Example of a MS/MS mass spectrum. 
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Figure 2.2.  Example of a MS/MS mass spectrum. The spectrum is a mass spectrometry 
output that displays the fragmented peptide ions within a sample. The theoretical peptide is 
fragmented into b and y ions, which are measured by their relative abundance and mass-to-
charge ratios. 
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Table 2.1 Ovarian tumor sample list. 
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				Western	Blot	of	Immunoprecipitated	HLA	class	I		
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Representative image of an HLA immunoprecipitation validation by 
Western blot analysis from three ovarian cancer patients. 
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Figure 2.3. Representative image of an HLA immunoprecipitation validation by 
western blot analysis. Western blot of 3 different ovarian patient tumor sample HLA 
immunoprecipitations. Samples were stained with the pan-class I antibody W6/32 to 
determine the relative abundance of HLA-I found within the lysed tumor sample prior to 
mass spectrometry analysis.  
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All HLA immunoprecipitations were validated by Western blot analysis  to determine 
if the HLA class I protein concentration was sufficient and was comparable between each 
sample. Figure 2.3 is a representative figure of a peptide elution validation by Western blot 
analysis. We identified roughly 500 to 1500 peptides on average per tumor sample.  
To assess the most frequently eluted peptide-encoding genes found in the OVCA 
immunopeptidome, we analyzed 20 of the best peptide elutions. Figure 2.4 displays the top 
50 most frequently eluted peptide-encoding genes among these samples. Through this 
unbiased observation of the most frequently eluted peptide-encoding genes, it was revealed 
that majority of the peptide-encoding genes eluted are not therapeutically safe antigen 
targets.  
Finding TAAs with only limited or no cross-reactivity with primary tissues remained 
our primary goal in the selection of potential tumor antigen targets. We found that most of 
the samples expressed peptides from genes that are un-targetable due to their high expression 
in normal tissues. These peptides may show up in high abundance because of the size of the 
protein they encode for, or due to the high abundance of the protein in specific tissues. For 
example, we found that the gene that encodes for the protein Titin (TTN) appeared in our 
OVCA elutions significantly more than any other gene. Titin is a very large protein found in 
cardiac and muscle tissues, which is likely why Titin-derived peptides were found so 
frequently in our elutions. By utilizing the Genotype-Tissue Expression Portal (GTex) 
database, which contains RNA sequencing on samples collected from 55 primary tissue sites 
from >3000 individuals, we can further analyze the therapeutic safety of each gene. 
The relative RNA transcript expression of a gene in each tissue can be represented in 
transcripts per million (TPM). TPMs can range from zero, which is essentially no transcript 
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expression, up to the thousands indicating extremely high gene expression. We were 
specifically searching for TAAs that have the lowest expression in normal tissues. Zero 
TPMs represents ideal transcript expression in primary tissues. However, the vast majority of 
peptides we eluted were derived from genes that also had some level of transcript expression 
in normal tissues. 
Primary tissues from the GTex were split into four safety categories that reflected the 
potential toxicities expected from off-target killing activity by antigen-specific CTLs (Table 
2.2).  These categories ranged from extremely dangerous (essential), hazardous, dangerous, 
and likely okay (non-essential). Table 2.2 contains examples of some of the normal tissues 
within each category along with the acceptable TPM thresholds for each category transcripts. 
All peptide-encoding genes were screened based on their TPM expression in each of the 
GTex normal tissues. Tumor-associated antigen transcript expression up to 30 TPM 
maximum was allowed in non-essential tissues (such as prostate, breast, and adipose tissues). 
A maximum expression threshold of 1 TPM was imposed for highly essential tissues such as 
heart and brain, for which CTL recognition can be lethal [97], [98].   
As observed with TC –T targeting of MAGE-A3, lethal cross-reactivity with other 
peptides that share similar sequences is a serious concern [97, 99].  To provide additional 
validation for our selected high-confidence peptide matches, they were analyzed by BLAST 
searches to identify all potential source genes. This helped to eliminate peptide candidates 
derived from multiple genes that may induce cross-reactivity. However, it is not currently 
possible to identify all potential peptide cross-reactivies in silico. 
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				Top	50	eluted	peptide-encoding	genes	from	OVCA	tumor	specimens	
 
 
 
Figure 2.4. Unbiased look at the top 50 most frequently eluted peptide-encoding genes 
in OVCA. Graph displaying the top 50 peptide-encoding genes eluted from 20 ovarian 
cancer tumor samples.  
 
 
 
Figure 2.4. Unbiased look at the top 50 genes encoding for the most frequently eluted 
peptides in OVCA. 
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Maximum	RNA	Transcript	Thresholds	for	TAA	expression	in	Normal	Tissues	
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Potential toxicity of TAAs based on primary tissue TPM expression. Table 
displaying the RNA transcript expression thresholds cutoffs for potential TAA in normal 
tissues. 
 
 
 
 
 
 
 
 
 
 
 
Extremely	
Dangerous	
Tissues 
Hazardous 
Tissues 
Dangerous 
Tissues 
Likely	Okay	
Tissues 
Heart,	Brain Liver,	Kidney,	
Colon,	Lung,	
Stomach 
Esophagus, 
Whole	Blood	,	
Bladder,	
Pancreas 
Breast,	Testis,	
Skin,	Ovaries 
1	TPM	or	lower 3	TPM	or	lower 10	TPM	or	lower 30	TPM	or	lower 
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Examining GTEx normal tissue gene expression, we concluded that Titin was clearly 
not a safe targetable tumor antigen [97]. Despite its significant abundance in our OVCA 
tumor sample elutions (Figure 2.5). Titin is expressed >300 TPM in skeletal muscle and >50 
TPM in the heart muscle. Since our dangerous threshold cutoff for the heart tissues was 1 
TPM the expression of Titin eliminated it as a potentially safe therapeutic TAA. 
Although the GTex provided some insights into gene expression for primary tissues, 
putative TAA genes were also screened for expression and in different cancer types through 
analysis of The Cancer Genome Atlas (TCGA) RNA sequence database. The TCGA contains 
whole exosome and RNA sequencing data from over 20,000 patients with over 35 different 
cancer types (Table 2.3).  
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Expression	of	Titin	in	normal	tissues	
 
 
 
 
 
 
 
 
 
Figure 2.5. Expression of the gene Titin in normal tissues.	
 
Figure 2.5. Expression of the gene Titin in normal tissues.  RNA expression of the gene Titin in normal 
tissues. The x-axis displays the transcripts per million. The y-axis displays the primary tissues. Data Source: 
GTEx Analysis Release V8.  
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Abbreviation Cancer Type 
LAML Acute Myeloid Leukemia 
ACC Adrenocortical carcinoma 
BLCA Bladder Urothelial Carcinoma 
LGG Brain Lower Grade Glioma 
BRCA Breast invasive carcinoma 
CESC Cervical squamous cell carcinoma and 
endocervical adenocarcinoma 
CHOL Cholangiocarcinoma 
LCML Chronic Myelogenous Leukemia 
COAD Colon adenocarcinoma 
CNTL Controls 
ESCA Esophageal carcinoma 
FPPP FFPE Pilot Phase II 
GBM Glioblastoma multiforme 
HNSC Head and Neck squamous cell carcinoma 
KICH Kidney Chromophobe 
KIRC Kidney renal clear cell carcinoma 
KIRP Kidney renal papillary cell carcinoma 
LIHC Liver hepatocellular carcinoma 
LUAD Lung adenocarcinoma 
LUSC Lung squamous cell carcinoma 
DLBC Lymphoid Neoplasm Diffuse Large B-cell 
Lymphoma 
MESO Mesothelioma 
MISC Miscellaneous 
OV Ovarian serous cystadenocarcinoma 
PAAD Pancreatic adenocarcinoma 
PCPG Pheochromocytoma and Paraganglioma 
PRAD Prostate adenocarcinoma 
READ Rectum adenocarcinoma 
SARC Sarcoma 
SKCM Skin Cutaneous Melanoma 
STAD Stomach adenocarcinoma 
TGCT Testicular Germ Cell Tumors 
THYM Thymoma 
THCA Thyroid carcinoma 
UCS Uterine Carcinosarcoma 
UCEC Uterine Corpus Endometrial Carcinoma 
UVM Uveal Melanoma 
Table 2.3 List of TCGA cancer types 
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By assessing the TCGA tumor expression data relative to the GTex normal tissue 
expression, an TAA over-expression index was calculated (Figure 2.6) (OV-index). The OV-
index took into account the average TPM expression of the eluted peptide-encoding genes in 
tumors divided by the max TPM expression in essential tissues. This allowed for the filtering 
out of the high-confidence potentially dangerous peptide targets from the peptides that may 
be safer to target with T-cell based immunotherapies. 
For validation, each eluted peptide was also further assessed  for several parameters 
using bioinformatics algorithms, including Mascot Ion Score, MS1 mass differential (delta 
mass), and predicted binding to the patient’s HLA allotypes, as determined by high-
resolution HLA typing [100], [101]. The Mascot Ion score indicated how well the 
experimentally-derived sequence matches the database sequence. Ion scores typically ranged 
between 0-90. Only ion scores of 10 or greater were considered, with the best-matched 
peptides having scores >25.  The delta mass is a measure of the deviation between the 
measured peptide mass and the theoretical mass of the peptide, and is important for quality 
control. Delta masses between -3 and 3 ppm were considered high quality identifications, and 
peptides outside of this ran were excluded from further consideration [102]. 
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Figure 2.6. Formula used for the calculation of overexpression index.	
Figure 2.6. Formula used for the calculation of overexpression index.	The average TPM expression of 
the eluted gene in tumors divided by the max TPM expression in essential dangerous tissues determined the OV-
index.	
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The NetMHC and NetMHCpan algorithms determined predicted HLA binding of the 
peptides. A low nM affinity score indicates a stronger binding affinity for that peptide to a 
particular HLA allele. After selecting high-confidence peptides, targeted MS/MS analysis 
was sometimes performed to confirm the TAA peptide identity. As described in chapter I, 
targeted MS/MS allows for a more sensitive level of detection with higher-condifidence.  To 
validate peptides, we combined targeted MS/MS with the isotope labeling of the individually 
selected high-confidence peptides. In this process, we started by synthesizing a 13C/15N 
isotope-labeled synthetic peptide from the high confidence peptide candidates selected.   
The isotope-labeled peptide is analyzed by mass spectrometry along with the original 
unlabeled tumor-derived peptide. The mass spectra of the unlabeled and labeled peptide are 
matched against each other, while also taking into account the retention-window time. The 
retention-window time is an output that measures the time from injection to detection of a 
peptide. For peptide validation, both peptides should have similar, if not exact retention-
window times. Additionally, the peptide-derived spectra should be matching with the 
exception of shifted ion mass-to-charge ratios characteristic of the isotope-labeled peptide.   
The following section will discuss the candidate TAAs identified through our OVCA 
antigen discovery methods, and delve deeper into one specific peptide-derived from MUC16 
that was selected as a potentially safe therapeutic target based on the criteria outlined above.  
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2.2b.) A novel MUC16-derived peptide was identified in ovarian cancer  
From our screening and validation method, a total of 8 TAA peptides were identified 
from the 38 OVCA tumor specimens. Five of these peptides were from the gene, Mucin 16 
(MUC16) (Table 2.3); however, each peptide identified was from different patient OVCA 
tumor samples. We also identified three novel peptides encoded by mesothelin (MSLN). 
Although MSLN has been pursued as a TAA in  CTL-based and peptide vaccines trials, we 
ultimately decided against pursuing it [103-106].  Due to MSLN’s elevated expression in 
normal lung tissue at (88 TPM), Thus it was not deemed a safe target according to our 
criteria. 
 From the five peptides that we identified, we chose to pursue the HLA-B*07:02-
restricted peptide derived from MUC16.  The spectra for this MUC16-derived peptide, 
TPGGTRQSL, is shown in (Figure 2.7). We selected this TAA target for multiple reasons: 
First, the MUC16-derived peptide TPGGTRQSL was found in an OVCA sample and in a 
pancreatic tumor specimen from a patient expressing HLA-B*07:02.  Additionally, the 
MUC16-dervided peptide, TPGGTRQSL was also found in another HLA-B*0702 ovarian 
tumor sample by Schuster et al. [107]. Detecting this peptide in another patient with a 
different cancer type, suggested that it might be a shared tumor antigen target. This added 
another level of confidence to this peptide as a potentially valuable therapeutic target. The 
predicted high binding affinity to HLA-B*07:02 (16nM) also contributed to our confidence 
that this peptide might be expressed in these tumor types (Table 2.3).   
MUC16 was first isolated by MD Anderson’s own Dr. Robert Bast in 1981 [108]. It 
is the largest membrane-associated mucin, being over 22,000 amino acids in length. MUC16 
is expressed at very low levels in adipose tissue, the cervix, and salivary glands. However, 
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MUC16 is expressed under 1 TPM for all these tissues, while being highly over-expressed in 
several cancers, including ovarian, pancreatic, cervical, uterine, mesothelioma and lung 
(Figure 2.8). 
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Table 2.3. List of potential TAA-targets eluted from OVCA tumor specimens.	
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Figure 2.7. Mass spectra of MUC16-derived peptide TPPGTRQSL.	
	
Figure 2.7. Mass spectra of MUC16-dervied peptide TPPGTRQSL. Mass spectra of an HLA-B*0702-
restricted MUC16-derived peptide isolated from an ovarian cancer tumor specimen OV16-012. 	
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Figure 2.8. MUC16 mRNA transcript expression in normal tissues and tumors. 	
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Figure 2.8. MUC16 mRNA transcript expression in normal tissues and tumors. GTex mRNA 
transcript expression of MUC16 in normal tissues color-coded by extremely dangerous essential 
tissues (red), hazardous (orange), dangerous (yellow), and non-essential (green). This is versus the 
TCGA mRNA expression of MUC16 in multiple tumor types shown in grey. 	
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The MUC16 gene  and protein has a long history with ovarian cancer. MUC16 
(CA125) is an established biomarker for epithelial ovarian cancer progression [109, 110]. 
MUC16 also contains a proteolytic cleavage site that allows for a major portion to be 
released from the cell surface [111]. Circulating serum levels of MUC16 are monitored in 
EOC patients as a prognostic factor to determine if patients are responding to treatment or if 
there is a recurrence [112]. Since MUC16 is a self-antigen, the ability for MUC16 to detach 
from the surface of tissues and circulate may contribute to T cell tolerance. This possibility 
was something we considered might be a hindrance to our ability to isolate MUC16-specific 
T cells from the blood. Aside from MUC16 being a biomarker for EOC, it also is linked to 
ovarian and pancreatic cancer progression through its adhesion to epithelial mesothelin-
expressing cells. This interaction promotes the migration, invasion, and metastasis of these 
cancers [113-115]. This occurs through the upregulation of the cell motility protein, MMP-7, 
via the MAPK pathway [116].  Since MUC16 appeared to be a safe TAA target based on its 
low normal tissue expression, combined with its high over-expression in multiple cancers, we 
next proceeded to attempt to isolate T cells against the peptide TGGTRQSL.  
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2.2c.) Generation of MUC16-specific T cells from healthy donor peripheral blood 
To generate MUC16-specific T cells, we utilized guidance from our clinical 
collaborator, Dr. Cassian Yee, who has previously developed this protocol [114]. Our 
MUC16-derived peptide was restricted to HLA-B*07:02, but we also utilized an HLA-
A*02:01 MART-1 peptide as a positive control. The MART-1 peptide was used to generate 
MART-1 specific T cells alongside the generation of MUC16-specific T cells to ensure the 
protocol worked as expected. We began with a leukapheresis obtained from a healthy donor 
who expressed both HLA-A*02:01 and HLA-B*07:02 positive alleles.  
Donor PMBCs were stimulated twice with autologous dendritic cells (DCs) pulsed 
with either the MART-1 or MUC16 (TPGGTRQSL) peptide in the presence of IL-21. 
Following the two stimulations, the cultured cells were stained and sorted with either a 
MART-1/HLA-A*02:01 or MUC16/HLA*B07:02-PE-conjugated custom tetramer. The cells 
were also stained with CD8+ antibody to sort out tetramer-positive CD8+ T cells. The cells 
were analyzed by flow cytometry for double-positive cells. Following the stimulation double-
positive MART-1 cells presented at frequency of 18% , a relatively high frequency (Figure 
2.9). This indicated that this donor might possess a higher than normal frequency of MART-
1-specific T cells, compared to the average person. By contrast, after the stimulation, 
MUC16-specific T cells were barely detectable at, 0.069% (Figure 2.9).  
We sorted cells from multiple culture wells for each peptide and pooled the wells 
together to expand the sorted cells in a 12-day Rapid Expansion Protocol (REP). We 
obtained a total of 34,000-sorted MART-1 cells and 4,300 cells for MUC16. After REP and 
an additional sort for double-positives (DPs), we were able to expand the MART-1-specific 
T-cells to 35% DPs, but did not detect any MUC16-specific cells (Figure 2.9). Since 
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MUC16-specific T cells did not expand (Figure 2.9). This was an indication that potential 
high tolerance and low immunogenicity could be hindering our ability to isolate MUC16-
specific T cells. Despite these results, we opted to repeat this protocol with modifications 
using the same PBMC donor. 
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Figure 2.9. First approach for the generation of MART-1 and MUC16-specific T cells. 
 
 
MART-1	and	MUC16-specific	T	cells	Generation	
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Figure 2.9. Generation of MART-1 and MUC16-specific T cells. 
Figure 2.9. First approach for the generation of MART-1 and MUC16-specific T cells. (A) 
Schematic outlining the experimental procedure for generating antien-specific CD8+ T-cells from human 
donor PBMCs. (B) PBMCs isolated by leukapheresis were stimulated with autologous MART-1 and 
MUC16-peptide-pulsed dendritic cells (DCs).  After two stimulations CD8+ and MART-1 (middle row) 
and MUC16 (bottom row) tetramer-positive cells were sorted and expanded using a standard rapid 
expansion protocol (REP).   
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To increase the activation and expansion of low-frequency CD8+ T cells within the 
donor PBMCs, Lipopolysaccharide (LPS), a TLR4 ligand, was added during the two DC 
stimulations. Following the stims, the cells were stained for double MART-1 or MUC16 
tetramer and anti-CD8. Based on the MART-1 staining (13.6%)  it appeared that the LPS did 
not make a significant difference in the amount of MART-1 specific cells isolated. In this 
experiment a total of 42,000 MART-1 HLA-A*02:01 CD8+ T cells were collected. For the 
TAA MUC16, we still were not able to isolate very many double-positive cells. In total, we 
collected 9,826 MUC16-specific CD8+ T cells for the REP. After the 12-day REP, we 
successfully generated >95% tetramer-positive MART-1 specific T cells (Figure 2.10). This 
was a significant improvement over the initial attempt. However, MUC16-specific T cell 
generation did not fare as well, as we were unable to isolate substantial amounts of MUC16 
tetramer-positive CD8+T cells (Figure 2.10). However, after the initial REP we did proceed 
to undertake a second REP. Unfortunately, upon completion of the second 12-day REP, the 
number of double-positive MUc16-speific T cells was still inadequate for the purposes of 
studying their antitumor activity and therapeutic potential.  
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Figure 2.10. Second attempt at the generation of MART-1 and MUC16-specific T cells. 
MART-1	and	MUC16-specific	T	cells	Generation	
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Figure 2.10. Second approach for the generation of MART-1 and MUC16-specific T cells. 
Generation of MART-1 and MUC16-specific T cells. (A) PBMCs isolated by leukapheresis were 
stimulated with autologous MART-1 and MUC16-peptide-pulsed dendritic cells (DCs).  After two 
stimulations, CD8+ and MART-1 tetramer-positive cells were sorted and expanded using a standard 
rapid expansion protocol (REP).  (B) MUC16 1 tetramer-positive cells were sorted and expanded using a 
standard rapid expansion protocol (REP). A second REP was conducted following a low yield of the first 
REP. 
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2.2d.) Discussion 
  MUC16 is a well-characterized tumor-antigen originally discovered in ovarian cancer 
[108]. That has been a biomarker for the disease several for years. In addition, it is also a 
biomarker for multiple other cancers including, fallopian tube, endometrial, non-small lung, 
breast, gastrointestinal, and pancreatic cancers [117-119].  MUC16 plays a critical role in 
ovarian and pancreatic tumor invasion and metastasis [109, 115]. For several reasons, 
MUC16 fits the criteria of a safe therapeutic target for T-cell based immunotherapy. It has 
extremely low expression in normal tissues across the body while having elevated levels in a 
number of different cancer types.  However, attempting to isolate low-frequency T cells from 
the peripheral blood of a healthy donor, was challenging, which may explain why there are 
no currently-approved TCR therapies that target MUC16 [120], [121].   
MUC16 presents some of the same challenges we face in targeting non-mutated, 
over-expressed tumor antigens.  MUC16 is unique in that happens to be the largest known 
cell surface glycoprotein (at over 22,000 amino acids), with >50 extracellular tandem repeat 
domains [122],[123]. This presents a potential explanation for difficulties we experienced in 
breaking tolerance. Due to the large size of MUC16, it may share similar or matching 
stretches of amino acids with other mucins or proteins that are not safely targetable. All these 
factors may be contributing to the lack of immunogenicity of MUC16. 
Isolating high-affinity CTLs that recognized MUC16 proved too to be unsuccessful, 
even after adding LPS to help boost the activation of those low frequency MUC16-specific T 
cells. MUC16 is known to be expressed at low levels, primarily in female reproductive 
tissues, such as the fallopian tubes and cervix. We therefore used healthy male donor PBMCs 
to try to isolate MUC16-specific T cells, which we reasoned would increase our chances of 
	
	 	 	
	
69	
	
isolating T cells. Since not every person necessarily possess high-affinity MUC16-specific T 
cells, repeating the isolation approach different donors might yield a greater chance of 
success. Using PBMCs from a tumor-bearing patient to isolate T cells may also have been a 
plausible approach. It is possible that they could possess some TAA-specific T cells that have 
been exposed to MUC16 on tumors, but could be suffering from an immunosuppressive 
tumor microenvironment. If we could isolate T cells directly from these tumors, we may have 
better success at expanding them. Due to the unsuccessful generation of T cells specific for 
MUC16, we chose to end our pursuit of this TAA target. We instead began working on the 
isolation of T cells against a different TAA, VGLL1, in collaboration with Dr. Cassian Yee’s 
laboratory, as described in the next chapter. 
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CHAPTER III: 
IDENTIFICATION OF THE SHARED CANCER PLACENTA ANTIGEN 
VESTIGIAL-LIKE 1 IN PANCREATIC CANCER 
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3.1 Rationale for tumor antigen discovery in pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC), the most aggressive form of pancreatic 
cancer, remains notorious for its poor prognosis and high mortality rate, with its overall 5-
year survival rate of 8% being amongst the lowest of all cancer types [124, 125].  Early 
detection is unusual, with 85% of patients presenting with locally advanced or metastatic 
disease [126].  Progress towards effective treatment has been slow and the incidence of 
PDAC-related deaths has continued to rise [127],[128].  Despite some encouraging recent 
improvements in survival achieved through optimizing the sequencing of surgery and 
chemotherapy treatment regimens, developing new and effective therapeutic options remains 
a dire need for advanced-stage PDAC patients [129]. 
  Checkpoint inhibitor (CPI) therapies that act through non-specific activation of T 
lymphocytes have made a significant positive impact on long-term patient survival [130]. 
However, the benefits of CPI have mainly been limited to highly mutated tumor types like 
melanoma and lung adenocarcinoma that can express a large array of potential neo-antigen 
peptides in the context of surface HLA molecules [131],[128]. Tumor-infiltrating lymphocyte 
(TIL) therapy, in which individual cancer patients are re-infused with T cells expanded from 
their own tumors, has also shown great promise for inducing the regression of bulky 
tumors.[132],[133]  TIL are polyclonal and can recognize both patient-specific neo-antigens 
as well as shared tumor-associated antigens (TAA) such as melanocyte differentiation 
antigens (MDA) or cancer-testis antigens (CTA)[134], [135],[136]. Targeting of individual 
validated HLA class I-restricted TAAs through infusion of antigen-specific endogenous T-
cells (ETC therapy) or genetically engineered TCR-T cells has also proven successful at 
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inducing clinical responses in patients with melanoma and other solid cancers [137], [138] 
,[139] ,[140] ,[141]. 
CPI- and CTL-based immunotherapies have unfortunately not shown the same 
beneficial impact in treating PDAC patients [142], [143]. This lack of success has been 
attributed to the highly immune suppressive tumor microenvironment (TME) of PDAC, in 
addition to the relatively low mutational burden that contributes to a dearth of potential neo-
antigen targets [144], [120], [145], [146]. A number of potentially targetable HLA class I-restricted 
peptide antigens have been identified in PDAC, most notably those derived from 
carcinoembryonic antigen-related cell adhesion molecule (CEACAM), mucin 16 (MUC16), 
mesothelin (MSLN), and mutated KRAS, among others [147], [106], [148], [149], [150].  
Although promising, therapies targeting these TAAs have faced inherent limitations, 
including the induction of toxicities in non-tumor tissues, low prevalence of target antigen 
expression, or inability to break self-tolerance mechanisms that often hinders the generation 
of high-affinity CTL  [142], [104], [151].  With limited exceptions, clinical trials targeting 
these antigens have yielded disappointing results, underscoring the need to identify 
immunogenic targets that demonstrate higher prevalence in PDAC patients. 
 
 
 
 
 
 
	
	 	 	
	
73	
	
3.2 Pancreatic cancer MS-based TAA discovery and antigen-specific T cell generation 
3.2a.)  Immunopeptidome analysis of PDAC patient tumors identifies tumor-
associated peptides  
To identify peptide targets for CTL-based immunotherapy of PDAC, we analyzed 39 
tumor specimens derived from 35 PDAC patients treated at M.D. Anderson Cancer Center. 
This included 34 freshly-excised surgical specimens (20 metastatic and 14 primary tumors), 
in addition to 3 patient-derived xenografts (PDX) and 2 organoid cell lines derived from 
metastases. Tumor cells were lysed and subjected to total HLA class I immunoprecipitation 
and acid elution, followed by tandem mass spectrometry (MS) to analyze the HLA-bound 
peptides. Eluted peptide fragmentation spectra were searched against the Swiss-Prot database 
(updated 9/2018) to identify matches encoded within the human proteome. Individual peptide 
matches were assessed using several orthogonal parameters, including Mascot Ion score, 
MS1 mass differential (delta mass), and predicted binding to the patient’s HLA allotypes as 
determined by high-resolution genetic sequencing [100], [101]. Further validation and 
potential suitability as therapeutic TAA targets was determined by evaluating all peptide-
encoding genes for (1) patient tumor tissue transcript expression as determined by RNAseq, 
(2) normal tissue transcript expression (GTex Portal database), and (3) overall expression in 
tumor tissues (TCGA database) (Figure 3.3A). (http://www.gtexportal.org/home/, 
http://cancergenome.nih.gov/) 
The amount of immunoprecipitated HLA class I correlated with the size of the fresh 
tumor specimens analyzed (R2 = 0.79), with the exception of 8 tumors (21.6%) that showed 
low HLA class I expression as assessed by Western blot analysis (Figure 3.1, Table 3.1). As 
expected, HLA class I protein levels also correlated with the number of Swis-Prot database 
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matches to eluted peptides (R2 = 0.62, Figure 3.2). Overall, the 39 tumor specimens analyzed 
yielded a total of 23,245 unique, high confidence peptide identities, of which 7,966 peptides 
(34.3%) were 8- to 13-mer peptides predicted to bind to one or more patient HLA class I 
allotypes. Fresh tumor specimens yielded a highly variable number of peptides, ranging from 
238 to 1657 (mean = 542). For 3 patients, PDX derivation resulted in larger tumor 
specimens, yielding an increased number of eluted peptides in all 3 cases. One of the two 
patient-derived organoid cell lines (MP015) yielded the highest number of eluted peptides 
overall (n = 1903), underscoring the quantitative advantage provided by expanding tumor 
specimens in vitro prior to MS analysis (Table 3.1, Figure. 3.2). 
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Quantity	of	immunoprecipitated	HLA	class	I	correlates	with	PDAC	tumor	specimen	
weight.	
Figure 3.1 Quantity of immunoprecipitated HLA class I correlates with PDAC tumor specimen 
weight. 
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Figure 3.1 Quantity of immunoprecipitated HLA class I correlates with PDAC tumor 
specimen weight. Surgical tumor resections from PDAC patients (n=36) or patient-derived 
xenografts (n=3) was weighed prior to tissue lysis and immunoprecipitation of total HLA class I 
using mAb W6/32. Recovered HLA class I was quantitated based on Western blot analysis by 
assessing the HLA class I band intensity (expected size 42 - 44 KD) on a scale of 0 (none detected) to 
4 (highest level detected). Graph shows specimen weight plotted by Western blot band intensity; the 
dotted line delineates samples with lower than expected HLA class I recovery, indicating reduced 
tumor HLA expression. 
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	Total	number	of	detected	PDAC-associated	peptides	correlates	with	quantity	
of	recovered	HLA	class	I.	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Total number of detected PDAC-associated peptides correlates with quantity of recovered 
HLA class I. 
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Figure 3.2 Total number of detected PDAC-associated peptides correlates with quantity 
of recovered HLA class I.  HLA class I recovered from patient-derived surgical resections (n=36), 
xenografts (n=3), or organoid cell lines (n=2) was quantitated by Western blot analysis by assessing 
the HLA class I band intensity (size 42 - 44 KD) on a scale of 0 (none detected) to 4 (highest level 
detected). Peptides eluted from immunoprecipitated HLA class I were analyzed by tandem MS and 
searched against the SwissProt human proteome database. Graph shows number of unique, high 
quality peptide matches (Mascot Ion score of 20 or higher) plotted against HLA class I intensity, as 
analyzed by Western blot. 
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3.2b.) Expression profiling of peptide-encoding genes identifies VGLL1 as a novel 
pancreatic cancer TAA 
 
To evaluate if any of the eluted peptides constituted safe therapeutic CTL targets, 
peptide-encoding genes were individually assessed for normal tissue transcript expression 
with reference to the GTex Portal database containing RNAseq data of 42 different human 
tissues. Normal tissues (excluding testis) were categorized into 4 groups that reflected the 
potential toxicities expected from off-target killing activity by antigen-specific CTLs (Table 
2.2). Peptide-encoding genes were then screened using four corresponding expression filters 
of increasing stringency in order to eliminate candidate TAAs most likely to elicit 
autoimmune toxicity in the context of CTL therapy (Figure 3.3B). Thus, while TAA 
transcript expression up to 30 TPM maximum was allowed in non-essential tissues (such as 
prostate, breast, and adipose tissues), a maximum expression threshold of 1 TPM was 
imposed for highly essential tissues such as heart and brain, for which CTL recognition can 
be lethal.[97], [98]. Using these stringent criteria, 12 TAA peptides were deemed safest to 
target, the genes encoding these peptides being MUC16 (encoding 5 unique peptides), 
MUC19, ZNF717, EIF5AL1, RGPD1, SLC30A8, MIA2, and VGLL1 (each encoding 1 unique 
peptide). Peptides encoded by TAAs MSLN and IDO1 were also detected, but were excluded 
in the screening due to elevated RNA transcript expression in normal lung tissue (88 TPM 
and 16 TPM, respectively, Figure 3.3B). Amongst the TAAs deemed safest to target, only 2 
peptides (derived from MIA2 and VGLL1) were found to be presented by tumors of more 
than one PDAC patient (Table 3.1).  
The 10-mer peptide LSELETPGKY, uniquely encoded by VGLL1, was eluted from 
both PDAC patient-derived organoid cell lines MP015-Org and MP081-Org. This peptide 
was predicted to bind with high affinity to HLA-A*0101 (51 nM), and RNAseq analysis 
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confirmed high VGLL1 transcript expression in both organoid lines (Table 3.1). Peptide 
identity was confirmed by targeted LC-MS, in which a synthetic peptide was analyzed as part 
of a mixture with organoid tumor-associated peptides. As shown in Figure 3.3C, the 
synthetic isotope-labeled peptide LSELETPGKY generated a highly similar fragmentation 
spectra to the native VGLL1 peptide detected from PDAC organoid lines MP015-Org and 
MP081-Org, and was also detected at nearly identical LC-MS retention times. Targeted MS 
analysis on 2 additional HLA-A*0101-expressing cell lines (PANC10.05 and BXPC3) 
demonstrated that the same peptide was also presented by PANC10.05, providing further 
evidence that LSELETPGKY might constitute a widely shared TAA (Figure 3.4). 
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Figure 3.3. Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by 
two PDAC patient-derived organoid lines. 
 
 
 
 
 
	Immunopeptidome	analysis	reveals	a	VGLL1-derived	peptide	expressed	by	two	PDAC	
patient-derived	organoid	lines.	
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Figure 3.3. Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by 
two PDAC patient-derived organoid lines. 
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Figure 3.3. Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by 
two PDAC patient-derived organoid lines. (A) Experimental strategy to identify PDAC 
tumor-specific, HLA class I-bound peptides from 41 tumor specimens derived from 36 M.D. 
Anderson PDAC patients. (B) Bioinformatics screening strategy to identify potentially 
targetable TAAs from amongst the eluted PDAC-associated peptides. Peptide-encoding 
genes were assessed for PDAC tumor RNAseq expression compared with transcript 
expression in 42 GTex Portal normal tissues. Excluding testis, normal tissues were separated 
into 4 categories (non-essential, caution, hazard, and danger tissues) that reflected the 
potential toxicities expected from off-tumor killing activity against different tissues (Table 
2.2). All peptide-encoding genes were filtered successively using four corresponding 
expression thresholds of increasing stringency (30, 10, 3, and 1 TPM, indicated by green 
dotted lines) to eliminate candidate TAAs most likely to elicit autoimmune toxicity in the 
context of CTL therapy (red dotted lines). Screening of high-confidence peptides isolated 
from tumor organoid cell lines of PDAC patients MP015 and MP081 is depicted, showing 
that only a few eluted peptides met these stringent safety criteria. (C) Mass spectra of an 
HLA-A*0101-restricted VGLL1-derived peptide isolated from two different organoid cell 
lines, MP015 and MP081 (top 2 panels). The patient-derived peptides co-eluted with and 
matched the MS fragmentation spectra of the synthetic isotope-labeled VGLL1 peptide 
LSELETPGKY (containing a 13C/15N-labeled lysine residue), with the labeled y+ fragment 
ion series demonstrating an expected shift of 8 atomic mass units (bottom panel). 
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VGLL1-derived	peptide	was	eluted	from	the	PANC-1005	cell	line	
	
Figure 3.4 VGLL1-derived peptide was eluted from the PANC-1005 cell line. 
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Figure 3.4 VGLL1-derived peptide was eluted from the PANC-1005 cell line. Mass 
spectra of HLA-A*0101-restricted VGLL1-derived peptide isolated from PDAC cell line 
PANC-1005 (top panel). This native peptide co-eluted with and matched the MS 
fragmentation spectra of the synthetic isotope-labeled peptide LSELETPGKY containing a 
13C/15N-labeled lysine residue (bottom panel). 
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3.2c.) VGLL1 is expressed by multiple cancer types and is associated with poorer 
overall survival  
VGLL1, also known as TONDU, was first identified as the human homolog of the 
Vestigial (Vg) protein in Drosophila, a key regulator of wing development [152], [153]. 
Since VGLL1 is a transcriptional co-activator that binds to the TEA domain family of 
transcription factors (TEFs) implicated in cancer development, we further examined VGLL1 
transcript expression in the 31 cancer types listed in The Cancer Genome Atlas (TCGA). As 
shown in (Figure 3.5A), in comparison to most normal tissues, VGLL1 is overexpressed in a 
number of different cancer types, including PDAC, bladder, ovarian, breast, lung, and 
stomach cancer. Interestingly, VGLL1 appears to be preferentially expressed in basal-like 
breast cancers while demonstrating a relatively low prevalence in other breast cancer 
subtypes (Figure 3.6). A similar tumor-associated expression profile was confirmed by 
microarray gene expression analysis of tumor cell lines listed in the Cancer Cell Line 
Encyclopedia (CCLE, Figure 3.7). According to the GTex RNAseq database, the highest 
median VGLL1 transcript expression was found in 3 non-essential tissues: bladder (15.3 
TPM), salivary gland (3.9 TPM), and breast (1.3 TPM). The highest level of VGLL1 
transcript expression in essential tissues was in normal lung (1.0 TPM), esophagus (0.73 
TPM), and kidney (0.34 TPM), while VGLL1 expression in heart and brain tissues was 
virtually undetectable (Figure 3.5A). Collectively, this data suggested that VGLL1 may 
constitute a safe, targetable TAA for multiple cancer types. 
 We next assessed if tumor VGLL1 transcript expression was associated with cancer 
patient survival. As shown in Figure 2B, TCGA PDAC patient survival (n = 175) was found 
to be inversely correlated with VGLL1 expression: patients with high expression had a 
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significantly shorter overall median survival compared to patients with low or absent 
expression (16 months vs. 37 months, p=0.001). This was confirmed in a independent cohort 
of 37 M.D. Anderson PDAC patients for whom PDX tissues could be derived: patients 
showing an overall survival of less 18 months demonstrated a significantly higher mean PDX 
VGLL1 expression compared to patients that survived longer than 36 months (57.3 TPM vs. 
9.6 TPM, p=0.003, Figure 2C). It is worth noting that VGLL1 transcript expression was 
found to be considerably higher in PDAC tumor cell lines and PDX tissues compared with 
surgically resected PDAC tumors, perhaps due to the high stromal content of many PDAC 
tumors in situ (Figures. 3.5A, 3.5C, Table 3.1). Highly elevated VGLL1 expression was also 
associated with shorter overall survival time in breast cancer (p = 0.037) and stomach cancer 
(p = 0.047), but showed no association with survival in ovarian cancer (Figure 3.8) [154].  
Interestingly, low or absent VGLL1 expression was associated with shorter survival time in 
bladder cancer (p = 0.036). One possible explanation is that loss a normal bladder tissue 
antigen like VGLL1 may indicate tumor dedifferentiation, which has been associated with 
poorer prognosis in bladder cancer and other tumor types [155].   
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Figure 3.5 VGLL1 is overexpressed in multiple tumor types and is associated with poor 
pancreatic patient survival. 
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Figure 3.5 VGLL1 is overexpressed in multiple tumor types and is associated with poor 
pancreatic patient survival. (A) VGLL1 transcript expression in normal tissues (colored 
dots, GTex Portal database) and human cancers (black dots, TCGA database), as determined 
by RNAseq analyses. Each dot represents one normal donor or patient tumor sample. Colors 
correspond to the 4 normal tissue categories defined in Figure 1: Green, non-essential tissues; 
Yellow, caution tissues; Orange, hazard tissues; Red, danger tissues. Although >95% of 
analyzed normal GTex caution, hazard, and danger tissue samples fell below 3 transcripts per 
million (TPM, dotted line), many TCGA cancer specimens demonstrate VGLL1 expression 
well above this threshold. (B) Kaplan-Meier curves showing TCGA PDAC patient overall 
survival (OS) stratified by tumor VGLL1 transcript expression (n = 175). P-values indicate 
log-rank significance test results comparing the OS of 3 groups of VGLL1-expressing 
patients to those patients with low or absent VGLL1 expression. (C) Patient-derived 
xenografts (PDX) from an independent cohort of MD Anderson metastatic PDAC patient 
tumors (n = 37) underwent RNAseq analysis after being grown in immunodeficient mice. 
Stratification of these PDAC patients into 3 groups corresponding to OS time showed that 
mean VGLL1 transcript expression was significantly associated with shorter patient survival 
time.  
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Figure 3.6 VGLL1 is preferentially expressed in basal-like breast cancer compared to other 
breast cancer subtypes.  
	
Basal-like	subset	of	Breast	Cancer	shows	elevated	VGLL1	Expression	
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Figure 3.6 VGLL1 is preferentially expressed in basal-like breast cancer compared to 
other breast cancer subtypes. TCGA breast cancer patients were subdivided into 5 major 
sub-types (LumA, LumB, Basal-like, HER2 overexpressing, and normal-like) and analyzed 
for tumor VGLL1 expression by RNAseq analysis. Each dot represents one TCGA patient 
sample, and VGLL1 transcript expression is expressed in fragments per kilobase of transcript 
per million mapped reads (FPKM). 
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VGLL1	prevalence	and	expression	in	CCLE	tumor	cell	lines	
Figure 3.7 VGLL1 gene expression in tumor cell lines derived from a variety of cancer types.  
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Figure 3.7 VGLL1 gene expression in tumor cell lines derived from a variety of cancer types. 
Gene expression microarray analysis of a diverse array of tumor cell lines (n=679) from the Cancer 
Cell Line Encyclopedia (CCLE) showed that VGLL1 is expressed by a majority of PDAC and bladder 
cancer cell lines, in addition to a significant percentage of breast, gastric, ovarian, and lung cancer cell 
lines. No VGLL1 expression was found in cell lines derived from melanoma, thyroid, or hematopoietic 
cancers. Threshold for VGLL1 antigen positivity was 3-fold above background signal.	
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High	tumor	VGLL1	expression	is	associated	with	reduced	survival	in	stomach	
and	breast	cancers	
Figure 3.8 High tumor VGLL1 expression is associated with reduced survival in multiple cancer 
types. 	
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Figure 3.8 High tumor VGLL1 expression is associated with reduced survival in multiple cancer 
types. TCGA cancer patients were stratified into three groups according to tumor VGLL1 expression 
as determined by RNAseq analysis. Kaplan-Meier curves show overall survival (OS) of each group for 
(A) Stomach adenocarcinoma, (B) Breast carcinoma, (C) Ovarian serous adenocarcinoma, and (D) 
bladder urothelial carcinoma patients. P-values indicate log-rank significance test results comparing the 
OS of the groups with the lowest and highest VGLL1 expression (blue vs. red).	
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3.2d.) VGLL1 is part of a unique group of Cancer-Placenta Antigens (CPAs) with 
therapeutic potential 
 
VGLL1 had been previously identified as having a regulatory role during early events 
in human placental development, and is a specific marker of proliferative cytotrophoblast 
[156]. In accordance with this, RNAseq gene expression data from 7 human placenta 
samples showed that VGLL1 demonstrates the highest expression in this tissue by a large 
margin (mean = 302.7 TPM),  nearly 20-fold higher than its expression normal bladder 
(Figure 3.9A). This led us to explore the notion that cancer-placenta antigens (CPA) may 
constitute a distinct category of targetable TAAs analogous to cancer-testis antigens (CTAs), 
which have been successfully targeted with CTL-based therapies. To identify other CPAs 
with similar expression profiles to VGLL1, we searched the GTex, TCGA, and other 
RNAseq databases for genes that demonstrated the following attributes: (1) highest normal 
tissue expression in placenta; (2) low to absent expression in other normal tissues; and (3) 
elevated expression in pancreatic, breast, bladder, and/or ovarian cancer. This search yielded 
9 additional genes, including Placenta-specific 1 (PLAC1), previously identified as a target of 
humoral antitumor immunity in cancer patients[157]. Interestingly, Chorionic Gonadotropin 
(CG) Beta subunits 3 and 5 (CGB3/CGB5), components of the CG hormone complex 
produced by placental trophoblasts during pregnancy, were also identified as potential CPAs 
due to their overexpression in a subset of pancreatic, testicular, uterine, and bladder cancers 
(Figure 3.10B). The other 6 putative CPAs demonstrated diverse expression profiles, ranging 
from those found only in a restricted set of cancer types (IGF2BP3, ADAM12), to those 
overexpressed in most cancer types but also demonstrating elevated expression in normal 
female reproductive tissues (CAPN6, MMP11) (Figure 3.9, Figure 3.10.). Although we did 
not detect peptides derived from these genes in this set of PDAC specimens, epitopes from 
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several of these putative CPAs have been identified in multiple tumor types and are listed in 
the Immune Epitope Database (IEDB) [157]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	 	 	
	
100	
	
 
 
 
Figure 3.9 VGLL1 is a cancer-placenta antigen (CPA) demonstrating high expression in normal 
placenta and tumors.	
VGLL1	is	a	cancer-placenta	antigen	(CPA)	demonstrating	high	expression	in	
placenta	and	tumors	
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Figure 3.9 VGLL1 is a cancer-placenta antigen (CPA) demonstrating high expression in 
normal placenta and tumors. Gene expression profiling uncovered 9 additional putative 
CPAs with similar expression profiles to VGLL1. (A) Heatmap depicting the mean transcript 
expression of different CPAs in normal placenta (top), GTex normal tissues, and transformed 
lymphocytes and fibroblasts (bottom). Tissues are listed in order of highest to lowest VGLL1 
expression, as determined by RNAseq analysis. (B) Heatmaps displaying the mean CPA 
transcript expression (left) and frequency (right) of CPA-positive tumor specimens in 34 
different TCGA cancer types as determined by RNAseq. CPA-positive specimens were 
defined as having tumor CPA transcript expression >5 TPM. Tumor tissues are listed in order 
of highest to lowest VGLL1 prevalence. 
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Figure 3.10 Expression of cancer-placenta antigens (CPAs) in all TCGA tumor 
specimens. 
 
 
 
 
 
 
Mean	expression	of	cancer-placenta	antigens	in	all	TCGA	tumor	specimens	
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Figure 3.10 Expression of cancer-placenta antigens (CPAs) in all TCGA tumor 
specimens. Gene expression profiling to search for potential TAAs with similar expression 
profiles to VGLL1 uncovered nine additional putative CPAs. Heatmap depicts the mean 
transcript expression of all 10 CPAs in 34 different TCGA cancer types, as determined by 
RNAseq. Tumor tissues are listed in order of highest to lowest mean VGLL1 transcript 
expression. 
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3.3 Generation and validation of VGLL1-specific T cells 
3.3a.) VGLL1-specific cytotoxic T cells were expanded from the peripheral blood of PDAC 
patient MP015 
 
Patient MP015 was a previously healthy 50-year old male first diagnosed with 
primary PDAC in December 2011. Two years following surgical removal of the primary 
pancreatic tumor, a thorascopic wedge resection of a left lung lesion was performed in 
November 2013 and used to derive organoid cell line MP015-Org [158]. The disease was 
kept in check for nearly 2 more years through a series of chemotherapeutic regimens, but 
following progression he was enrolled in an IRB-approved cell therapy protocol at M.D. 
Anderson to receive autologous, expanded tumor-antigen-specific CTLs. Immunopeptidome 
analysis performed on the expanded organoid cell line MP015-Org in May 2015 led to the 
identification of 6 HLA class I-bound peptides (4 derived from MUC16 and 1 each from 
ZNF717 and VGLL1) that met our criteria as safe, targetable TAAs (Table 2.3). Custom 
clinical-grade tetramers were available for 3 of the 6 potential targets: two HLA-B*3502-
restricted MUC16 peptides and the single HLA-A*0101-restricted VGLL1 peptide. 
  Following leukapheresis, patient MP015 PBMCs were stimulated twice with 
individual peptide-pulsed DCs in the presence of IL-21, followed by tetramer-based sorting 
of antigen-specific CD8+ T cells (Figure 3.11A). Although MUC16-specific CTLs failed to 
expand from patient PBMC, VGLL1 CTLs expanded successfully, with VGLL1 tetramer-
positive T cells comprising 3.4% of CD8+ after 2 weeks of DC-peptide stimulation (Figure. 
3.11B). Cell sorting followed by employment of the rapid expansion protocol (REP) was 
repeated twice, resulting in nearly 20 billion expanded CTLs, of which >90% were VGLL1 
tetramer-positive and demonstrated restricted Vβ usage (Figure 3.11B and C). VGLL1-
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specific CTLs were also successfully expanded from 2 of 2 healthy HLA-A*0101-positive 
blood donors, demonstrating the general immunogenicity of the LSELETPGKY peptide 
(Figure 3.12).  
Expanded CTLs from patient MP015 were tested functionally using standard 51Cr 
release assays. Mel888 melanoma cells (VGLL1-negative, HLA-A*0101 positive) pulsed 
with titrated amounts of VGLL1 peptide elicited CTL recognition and killing at peptide 
concentrations as low as 10 nM, indicating relatively high affinity for cognate peptide 
(Figure 3.11D). Importantly, expanded patient-derived CTLs also showed robust recognition 
of the autologous organoid cell line MP015-Org from which the VGLL1 peptide was 
originally detected by MS (Figure 3.11A). In October 2015 following a pre-treatment 
regimen of Cytoxan, Patient MP015 was infused with 19.6 billion autologous, expanded 
VGLL1-specific CTL, subsequently receiving interleukin-2 and pembrolizumab. Although 
the patient experienced a transient fever (a frequent side effect of T-cell infusion-induced 
cytokine release), they experienced no adverse events indicating potential CTL-mediated 
toxicities. Unfortunately, scans in late November 2015 showed rapid disease progression 
manifested as an interval increase in lung lesions and pleural-based metastatic disease [158]. 
Surprisingly, biopsy of a pleural-based nodule at this time revealed a poorly differentiated 
neuroendocrine tumor. DNA sequencing analysis of serial liquid biopsies collected over the 
previous 18 months provided evidence of an extremely rapid evolution of Patient MP015’s 
cancer due to numerous progressive genetic amplifications, deletions, re-arrangements, and 
epigenetic changes. RNAseq analysis also demonstrated that a dramatic reduction in VGLL1 
transcript expression (35.1 TPM to 1.6 TPM) had occurred between December 2013 and 
December 2015, providing a potential explanation for the lack of clinical response to ETC 
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therapy (Figure 3.14). Patient MP015 expired in January 2016 due to extensive 
complications deriving from progression of his lung metastases [158]. 
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Mean	expression	of	cancer-placenta	antigens	in	all	TCGA	tumor	specimens	
Figure 3.11. Generation of VGLL1 antigen-specific CTLs from peripheral blood of Patient 
MP015. 
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Figure 3.11. Generation of VGLL1 antigen-specific CTLs from peripheral blood of 
Patient MP015. 
 
(A) Schematic outlining the experimental procedure for generating VGLL1-specific CD8+ T-
cells from human donor PBMCs. (B) PBMC isolated from PDAC Patient MP015 by 
leukapheresis were stimulated with autologous LSELETPGKY peptide-pulsed dendritic cells 
(DCs).  After two stimulations (top row), CD8+ and VGLL1 tetramer-positive cells were 
sorted and expanded using a standard rapid expansion protocol (REP).  VGLL1-specific T-
cells were re-sorted and expanded a second time due to low numbers of antigen-specific cells 
following the first REP. The second REP yielded 19.6 x 109 VGLL1-specific CTLs, which 
Patient MP015 safely received as an infusion under a personalized ETC therapy 
Compassionate IND protocol. TCR repertoire analysis of expanded VGLL1-specific CTLs 
was also performed using Vβ antibodies corresponding to 24 different specificities (bottom 
panels). (C) VGLL1-specific T-cells expanded from Patient MP015 were tested for 
functionality in a standard 51Cr release assay to assess specific lysis of Mel888 melanoma 
tumor cells (VGLL1-negative HLA-A*0101-positive) pulsed with titrated amounts of 
LSELETPGKY peptide at a 5:1 effector-to-target (E:T) ratio.  
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VGLL1-specific	CTLs	were	expanded	from	PBMC	of	multiple	donors	
Figure 3.12 Generation of HLA-A*0101-restricted VGLL1 antigen-specific CTLs from multiple normal 
donor PBMC.	
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Figure 3.12. Generation of HLA-A*0101-restricted VGLL1 antigen-specific CTLs from 
multiple normal donor PBMC. (A and B) Induction of VGLL1-specific CD8 T cells from PBMC 
of two healthy donors. HLA A*0101-expressing donor PBMC were stimulated with LSELETPGKY 
peptide-pulsed dendritic cells for 2 weeks. VGLL1 tetramer-positive CD8 T cells were sorted by 
ARIA sorter after 2 stimulations (top panels) and the sorted T cells were expanded using a standard 
rapid expansion protocol (REP). TCR repertoire analysis of expanded VGLL1-specific CTLs was 
performed using Vβ antibodies corresponding to 24 different specificities (bottom panels).  
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Figure 3.13 PDAC patient MP015 showed loss of VGLL1 antigen expression prior to VGLL1-
CTL therapy. 
 
 
 
 
 
RNAseq	analysis	of	lung	tumor	biopsies	revealed	loss	of	VGLL1	expression	in	
PDAC	Patient	MP015	
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Figure 3.13. PDAC patient MP015 showed loss of VGLL1 antigen expression prior to VGLL1-
CTL therapy. Serial liquid biopsies were acquired from the lung metastases of PDAC Patient 
MP015 at different time points during treatment at M.D. Anderson. Retrospective longitudinal 
RNAseq analyses of these samples revealed that VGLL1 transcript expression was lost in the months 
prior to receiving VGLL1-specific ETC therapy. 
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3.3b.) VGLL1-CTLs demonstrate cytotoxicity against multiple allogeneic PDAC tumor cell 
lines. 
Although Patient MP015 did not experience clinical benefit from adoptive transfer of 
his own VGLL1-specific CTLs, the robust antitumor activity demonstrated by these T-cells 
in vitro led us to explore whether they may possibly benefit other PDAC patients. HLA-
A*0101 was expressed by ~30% of our PDAC patient cohort, and RNAseq analysis of 
TCGA and MDACC PDAC surgical specimens and PDXs showed that 43.2% to 62.5% of 
patients express VGLL1 transcript at a level > 5 TPM. From these data, we estimate that 12% 
to 15% of PDAC patients present the LSELETPGKY peptide target in the context of HLA-
A*0101 and therefore could potentially benefit from VGLL1-CTL therapy.   
To determine if VGLL1-CTLs derived from Patient MP015 could recognize 
allogeneic PDAC tumors, we tested a panel of HLA-A*0101 expressing PDAC tumor cell 
lines as targets for killing using a 51Cr release assay. Western blot analysis was used to 
confirm VGLL1 protein expression, and flow cytometry confirmed surface expression of 
HLA-A*0101 in cell lines (Figure 3.15). While control cell line WM793 (VGLL1-negative, 
HLA-A*0101-positive) was not recognized, VGLL1-specific CTLs recognized autologous 
MP015-Org cells and 4 out of 4 allogenic PDAC lines tested, including inducing robust 
killing of PANC-1005, CAPAN-1, and BXPC3 (Figures 3.14A and B).  
The PDAC organoid cells derived from Patient MP081 were also lysed by VGLL1-
CTLs but with reduced efficiency, likely due to an outgrowth of VGLL1-negative cells 
within the culture (not shown). VGLL1-CTL specificity was demonstrated by co-incubation 
with the pan-MHC class I antibody W6/32, which resulted in blockade of PANC10.05 
recognition and lysis (Figure 3.16). Collectively, these results provide evidence that the 
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LSELETPGKY peptide constitutes a shared PDAC tumor antigen that can be effectively 
targeted with VGLL1-specific CTLs. 
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 Figure 3.14. VGLL1-specific CTLs recognize and kill multiple allogeneic pancreatic 
cancer cell lines. 
 
 
 
 
 
RNAseq	analysis	of	lung	tumor	biopsies	revealed	loss	of	VGLL1	expression	in	
PDAC	Patient	MP015	
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Figure 3.14. VGLL1-specific CTLs recognize and kill multiple allogeneic pancreatic 
cancer cell lines. (A) Expanded VGLL1-specific CD8+ T cells from Patient MP015 were co-
cultured with a panel of HLA-A*0101-positive PDAC tumor cell lines in a standard 51Cr 
release assay to measure cytotoxic activity at different effector-to-target (E:T) cell ratios. 
WM793 melanoma cells (VGLL1-negative HLA-A*0101-positive) were used as a negative 
control line. VGLL1-CTLs robustly killed the autologous organoid cell line MP015 from 
which the VGLL1 peptide was originally isolated, and also demonstrated cytotoxic activity 
against four allogeneic, HLA-A*0101-expressing PDAC cell lines. Results show the means 
and standard deviations of six replicate samples, and data is representative of a minimum of 4 
replicate experiments. (B) Western blot analysis confirmed expression of VGLL1 protein in 
all five PDAC cell lines tested. 
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Figure 3.15. HLA-A*0101 surface expression confirmed on target cell lines by flow 
cytometry.  
 
 
 
 
 
HLA-A*0101	surface	expression	on	tumor	cells	and	primary	cell	lines	
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Figure 3.15. HLA-A*0101 surface expression confirmed on target cell lines by flow 
cytometry. All tumor cell lines and normal primary cells used in this study were stained with 
fluorophore-labeled HLA-A*0101-specific mAb and analyzed by flow cytometry to confirm 
natural endogenous HLA-A*0101 surface expression (grey histograms) prior to use as targets 
in VGLL1-specific CTL assays. Five tumor cell lines were transduced to express HLA-
A*0101 using a lentiviral expression vector (red histograms). 
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Figure 3.16. VGLL1-CTL killing is blocked with an HLA-class I-specific antibody.  
 
 
 
 
 
 
 
 
 
 
HLA	Class	I	Blockade	abrogates	VGLL1-CTL	recognition	of	PDAC	cell	line	
PANC10.05	
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Figure 3.16. VGLL1-CTL killing is blocked with an HLA-class I-specific antibody. 
Expanded VGLL1-specific CD8+ T cells were co-cultured with HLA-A*0101-positive 
PDAC tumor cell line PNAC-1005 in a standard 51Cr release assay to measure cytotoxic 
activity at different effector-to-target (E:T) cell ratios. Addition of the HLA class I blocking 
antibody W6/32 largely abrogates VGLL1-CTL killing, demonstrating that antitumor activity 
is HLA class I-restricted. 
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3.3.c) VGLL1-CTLs show activity against multiple tumor types and reduced recognition of 
primary cells 
TCGA patient RNAseq data analysis indicated that VGLL1 is expressed by several 
cancer types (16 of 31), most notably in 75 - 80% of patients with bladder, ovarian, and 
basal-type breast cancers, and 15 - 20% of patients with lung and gastric cancers (Figure 
3.4). We therefore set out to determine whether cell lines derived from these cancer types 
could be targets for VGLL1-specific CTLs (Figure 3.17A). Western blot analysis of a panel 
of ovarian, basal-type breast, bladder, gastric, and lung cancer cell lines showed high VGLL1 
expression in 12 of 14 lines analyzed (Figure 3.17B). Of the 8 cell lines that naturally 
expressed HLA-A*0101, VGLL1-CTLs killed 2 of 3 ovarian lines, 2 of 3 breast lines, and 2 
of 2 bladder and lung cancer lines (Figure 3.17A). Five additional HLA-A*0101-negative 
cell lines (2 gastric, 2 bladder, and 1 lung line) were transduced to express HLA-A*0101 
prior to testing them as targets for VGLL1-CTLs. As shown in Figure 6A, all five HLA-
A*0101-transduced cell lines were rendered susceptible to killing by VGLL1-CTLs, 
indicating presentation of the LSELETPGKY peptide from processed, endogenously-
expressed VGLL1 protein. Taken together, these results suggest that VGLL1-CTLs have 
potential therapeutic value for at least five additional cancer types besides PDAC. 
To assess the safety of VGLL1-CTLs for potential therapeutic use, we tested them 
against a panel of normal primary cells most likely to elicit VGLL1-specific reactivity 
according to the GTex normal tissue expression profile. Since bladder demonstrated the 
highest normal tissue VGLL1 transcript expression, we tested two different HLA-A*0101 
positive primary bladder cell lines as targets for VGLL1-CTL killing. As shown in Figure 
13.8C, specific lysis was very low, detectable in one bladder line but only at the highest E:T 
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ratio. The GTex database indicated that VGLL1 transcript is also expressed at low levels in 
normal breast and lung (Figure. 3.3A). We therefore tested VGLL1-CTL killing activity 
against HLA-A*0101-expressing primary mammary and lung airway cells, along with 
primary melanocytes as a negative control. Of this panel, mammary cells elicited moderately 
high levels of killing by VGLL1-specific CTL, results that were consistent with VGLL1 
levels as assessed by Western blot (Figure 3.17D). By contrast, lung airway epithelial cells 
were not killed by VGLL1-CTLs, despite demonstrating ample HLA-A*0101 surface 
expression (Figure 3.15). These results provide supporting evidence that VGLL1-specific T 
cells are unlikely to recognize any essential normal tissues; however, safety concerns may be 
warranted due to the potential for reactivity against some non-essential tissues.  
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VGLL1-CTLs	kill	cell	lines	derived	from	multiple	cancers	but	show	reduced	
recognition	of	normal	primary	cell	lines 
	
Figure 3.17 VGLL1-specific T cells recognize and kill multiple tumor types, but have 
reduced recognition of primary tissue cell lines. 
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Figure 3.17. VGLL1-specific T cells recognize and kill multiple tumor types, but have 
reduced recognition of primary tissue cell lines. (A) VGLL1-specific CD8+ T cells were 
co-cultured with 12 different HLA-A*0101-expressing tumor cell lines derived from ovarian, 
lung, breast, bladder, or gastric cancer in a standard 51Cr release assay to measure cytotoxic 
activity at different effector-to-target (E:T) cell ratios. Five HLA-A*0101-negative cell lines 
(EBC1, HT1197, HT1376, GT-5, and MKN74) were lentivirally transduced to stably express 
HLA-A*0101; VGLL1-CTL killing of the parental cell lines (grey lines) are shown in 
comparison to HLA-A*0101-transduced counterparts (black lines). (B) Western blot analysis 
confirmed VGLL1 protein expression in 11 of 12 tumor cell lines derived from ovarian, lung, 
breast, bladder or gastric cancer. (C) VGLL1-specific CTLs were co-cultured with HLA-
A*0101-expressing primary tissue cells derived from bladder, breast, kidney, lung airway, or 
skin melanocytes in a standard 51Cr release assay to measure cytotoxic activity. VGLL1-CTL 
assay results show the means and standard deviations of six replicate samples, and data is 
representative of a minimum of 2 replicate experiments. (D) VGLL1 protein expression in 
primary cell lines, as accessed by Western blot analysis.  
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3.3d.) Discussion 
The benefits of immunotherapy have been slow to translate to PDAC, likely due to 
the relatively low mutational burden, highly suppressive tumor microenvironment, and a lack 
of known TAA targets for CTL therapies [159], [151]. Oncogenic driver mutations in KRAS 
represent particularly promising target epitopes due to their tumor specificity and high 
prevalence in PDAC, colorectal cancer (CRC), and lung cancer. In an exciting recent case 
study, CTLs expanded from TIL of a CRC patient specifically recognized an HLA-C*0802-
restricted KRAS peptide containing the G12D mutation; furthermore, these TIL were shown 
to mediate an objective tumor regression of multiple lung metastases in the patient following 
infusion [147].  While highly promising, the low worldwide prevalence of HLA-C*0802 
predicts that only ~1.5% of PDAC patients could benefit from targeting this mutated epitope. 
TCRs recognizing mutated KRAS epitopes restricted to HLA-A*1101 have also been 
reported; although not yet tested in clinical trials, the relatively high prevalence of A*1101 
predicts a significantly larger potential patient population that would be centered largely in 
Asia [160].  The lack of shared mutations beyond KRAS suggests that identification and 
targeting of non-mutated TAAs may represent the most promising opportunity for advancing 
immunotherapies for PDAC. Two well-studied TAAs for PDAC and ovarian cancer, MUC16 
and MSLN, illustrate the two principal challenges of targeting non-mutated TAAs: difficulty 
in breaking T-cell tolerance and, conversely, the potential for induction of on-target off-
tumor toxicities. Based on low overall normal tissue and relatively high tumor expression, 
MUC16 appears to be an ideal TAA; however, isolating high affinity CTLs that recognize 
non-mutated MUC16 epitopes has proven elusive [120], [121].  This lack of immunogenicity 
may be attributed to tolerogenic attributes of MUC16: being detectable at low levels in 
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healthy patient serum, and also being a very large protein (>22,000 AA) containing >50 
extracellular tandem repeat domains [122]. 
Employing an unbiased immunopeptidome analysis of tumor specimens derived from 
35 PDAC patients, VGLL1 was identified as a novel putative shared TAA, ranked second 
only to MUC16 in terms of tumor overexpression in comparison to essential normal tissues. 
However, in contrast to MUC16 epitopes, the HLA-A*0101 restricted VGLL1 peptide was 
considerably more immunogenic, capable of eliciting antigen-specific CTLs from multiple 
PBMC donors, including one PDAC patient. Such immunogenicity provides a significant 
advantage in the context of developing endogenous T-cell (ETC) therapies for cancer 
patients. HLA-A*0101 is expressed at a relatively high prevalence (25 to 30%) in Western 
European and North American countries, suggesting that these patient populations would be 
most likely to benefit from targeting this epitope [161]. Expanded VGLL1-specific CTLs not 
only recognized and killed a panel of allogenic PDAC tumor lines, but also demonstrated 
reactivity against A*0101-expressing tumor cells derived from five other cancer types. We 
estimate that targeting this single VGLL1 epitope could potentially benefit a large number of 
Western cancer patients, including over 20% of patients with ovarian, bladder, or basal-like 
breast cancers, ~12% of patients with PDAC, and 5 - 10% of patients with lung, stomach, 
cervical, uterine, or head and neck cancers.  
Higher VGLL1 expression has been associated with shorter patient survival in 
multiple cancer types, including triple-negative breast and endometrial cancers [154], [162].  
However, its negative impact on survival is most striking in PDAC (Figures 3.5 and 3.6), 
suggesting that VGLL1 may play a role in driving tumor aggressiveness.	VGLL1 is a co-
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transcriptional activator and a marker of proliferating cytotrophoblasts during early human 
placental development where it is co-expressed with the transcription factor TEAD4 [156], [163].  
The discovery of VGLL1 prompted us to search for other putative CPAs that 
demonstrated overexpression in placenta and tumors, and thus may constitute potential TAA 
targets. This search uncovered Placenta-specific 1 (PLAC1), initially identified as a target of 
autologous humoral immunity in gastric cancer and hepatocellular carcinoma patients, and 
the first CPA reported to represent a class of TAAs distinct from CTAs and oncofetal 
antigens [164], [165].  A TCR recognizing an HLA-A*0201-restricted peptide derived from 
PLAC1 was recently isolated and shown to possess antitumor activity against human breast 
cancer cells in pre-clinical models, but have not yet been tested in clinical trials [166]. As 
shown in Figure 3, PLAC1 shows low normal tissue expression, but also demonstrates low 
overall prevalence in cancer. By contrast, Insulin-Like Growth Factor 2 mRNA Binding 
Protein 3 (IGF2BP3) was also identified as a promising CPA in our screen, showing 
relatively high prevalence of expression in ~15 different cancer types, including 
glioblastoma, uterine, testicular, and lung cancers (Figure 3.7). The high level of IGF2BP3 
expression in normal testis, transformed lymphocytes and transformed fibroblasts suggests 
that this protein may also play a role in driving cancer progression, consistent with its 
identification as a poor prognostic factor [167], [168].  Unfortunately, IGF2BP3 shows a 
significant degree of amino acid identity with IGF2BP2, which is expressed at elevated levels 
in several essential normal tissues, thus limiting the number of safely targetable epitopes. Of 
the 10 putative CPAs identified, matrix metallopeptidase 11 (MMP11) showed the most 
striking expression and prevalence, being expressed at high transcript levels in 25 different 
cancer types (Figure 3.8). However, in addition to normal placenta, MMP11 is also 
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expressed at relatively high levels in uterus, cervix, and ovary, suggesting that CTL-based 
targeting of MMP11 epitopes may result in reproductive toxicities for women.       
 In terms of safety profile, cancer prevalence, and immunogenicity, VGLL1 compares 
favorably with other known TAA targets. Moreover, one male PDAC patient treated with 
autologous, high-affinity VGLL1-specific CTLs experienced no apparent autoimmune 
toxicities, providing evidence that VGLL1 can be safely targeted in vivo. However, in vitro 
testing did show significant VGLL1-CTL reactivity against cultured primary mammary cells, 
suggesting that gender-specific safety considerations should be taken into account when 
targeting CPAs. Immediate clinical applications of these findings include a planned clinical 
trial to treat HLA-A*0101+/VGLL1+ PDAC patients with VGLL1-specific ETC therapy, 
with future cohorts to potentially include bladder, ovarian, and/or breast cancer patients. 
VGLL1-specific TCRs derived from Patient MP015 have been cloned and are currently 
undergoing validation for future potential clinical applications, including TCR-T cell 
therapies. MS-based identification of additional VGLL1 epitopes restricted to other HLA 
allotypes is also ongoing, with the promise of expanding the number of treatment-eligible 
cancer patients [79].  Although single antigen-based CTL targeting can demonstrate limited 
clinical utility due to selection of antigen-loss variants, tumor debulking and subsequent 
epitope spreading constitute important aspects of immunotherapeutic success, processes that 
may be further augmented when combined with other modalities such as checkpoint 
blockade [137],[138]. Collectively, our study shows that VGLL1 is a promising TAA target 
that can be used in immune-based therapies to address a clear unmet need in patients with 
PDAC and multiple other cancers.  
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CHAPTER IV: 
 
CHARACTERIZING THE ROLE OF VGLL1 IN CANCER PROGRESSION 
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4.1.) VGLL1 is an important regulator of placental growth during embryo development 
and is associated with poor prognosis for pancreatic cancer patients.	
Through examining the immunopeptidome of pancreatic cancer, we identified 
VGLL1, as a novel cancer placenta antigen shared by multiple cancer types. However, the 
role of VGLL1 in cancer progression remains to be elucidated. In total, there are only 15 
peer-reviewed publications on VGLL1, and only a subset of these address the role of VGLL1 
in cancer. However, we can gleam some insights into its role from studies on primary tissues, 
since tumors often “hijack” normal functions of cells to benefit their growth and survival. In 
other words, by studying the role of VGLL1 in primary tissues, we may be able to infer what 
role it could play in cancer progression. 
As previously discussed in chapter 3, VGLL1 is a co-transcriptional activator and an 
important regulator of the proliferation of cytotrophoblasts during early human placental 
development. VGLL1 is co-expressed with the transcription factor TEAD4 in the hippo 
pathway [156], [163].    The hippo-signaling pathway controls organ size, tissue hemostasis, 
and regeneration [169]. The Human Protein Atlas (http://www.proteinatlas.org ) contains 
IHC staining of placenta tissues, in which VGLL1 is most highly expressed (>200TPM), 
mostly in the leading edge of the tissues (Figure 4.1). The outer edge of the placenta is 
where cytotrophoblasts are found. Cytotrophoblasts are both highly proliferative and 
extremely invasive. There are two forms of villous cytotrophoblast stem cells [170]. One 
form of cytotrophoblasts are the cells responsible for invading the mother’s tissue to help the 
placenta implant into the uterus [171]. The other form of trophoblasts spread to the arteries of 
the mother and bore into the vessels to create the blood flow connection between the mother 
and fetus during pregnancy [172].  
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Due to the known invasive VGLL1-expressing cytotrophoblasts, the expression of 
VGLL1 in tumor cells may and contribute to the aggressiveness of cancer. As shown in 
chapter 3, pancreatic cancer patients with elevated levels of VGLL1 had the shortest overall 
survival (Figure 3.5). Additionally, the most aggressive breast cancer subtype, basal-like 
breast cancer, possesses the highest expression of VGLL1 out of all breast cancer types 
(Figure 3.6).  
These two cancers are highly metastatic, and known to spread quickly to neighboring 
tissues [173]. Suggesting that VGLL1 expression may play a role in tumor metastasis. 
Furthermore, there appears to be a strong homology VGLL1 with the well established 
oncogenes YAP and TAZ within in the hippo pathway. In the next section, we will explore 
how the oncogenes YAP/TAZ may provide a blueprint to understand the role of VGLL1 in 
cancer progression. 
 
  
 
 
 
 
 
 
 
	
	
	 	 	
	
134	
	
	
	
	
	
	
	
	
	
Figure 4.1 IHC staining of placenta tissue from the Human Protein 
Atlas database. 
 
https://www.proteinatlas.org/ENSG00000102243-VGLL1/tissue/placenta#img 
 
 
Cytothrophoblasts	express	VGLL1	in	placenta	tissue	
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Figure 4.1 IHC staining of placenta tissue from the Human Protein Atlas. VGLL1 is 
expressed in the outer edge of the cells in placenta tissue by IHC staining. These VGLL1-
positive cells are cytothrophoblasts. 
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4.2.) VGLL1 shares similar binding motif to TEADs with the oncogenes YAP/TAZ in 
the hippo pathway. 
The Hippo signaling pathway is a highly conserved intracellular-signaling network 
that regulates cell proliferation, organ size, and regeneration [169]. The Hippo signaling 
pathway is co-opted in multiple cancers to drive tumor progression [174], [175]. Two well-
characterized oncogenes, YAP1 (Yes associated protein 1) and TAZ/WWTR1 (WW Domain 
Containing Transcription Regulator 1), function as co-transcriptional activators of the Hippo 
signaling pathway, and in cancers they, also bind to TEAD proteins, leading to the 
upregulation of several cancer-promoting genes (Figure 4.3) [152], [176], [177]. It is 
important to note that YAP and TAZ are two distinct proteins, but are often referenced 
together because they share mostly redundant functions within the Hippo signaling pathway 
[178].  
YAP is over-expressed in pancreatic cancer and has been linked to promoting factors 
such as tumorigenesis and chemoresistance (Figure 4.2). YAP has also been shown to 
promote EMT transition in pancreatic cancer, increasing cell motility, invasion, and 
tumorigenesis through hyperactivation of AKT signaling [176, 179, 180].  Additionally, 
YAP/TAZ were identified as partners to mutant KRAS in pancreatic cancer [169]. In vivo 
experimental models show that YAP/TAZ act as transcriptional activators downstream of 
KRAS, resulting in the upregulation of genes that promote proliferation and invasiveness 
[181].  These two genes have been well characterized in multiple cancers as also being 
associated with pro-inflammatory responses, migration, and immune evasion [182-184]. The 
interaction of YAP/TAZ with TEADs was shown to induce PD-L1 upregulation and 
inhibited T cell function when overexpressed in breast epithelial cells [185].  
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Figure 4.2 The Hippo signal pathway in pancreatic cancer. 
	
Figure	used	with	premission	from	author:	
	
Ansari D, Ohlsson H, Althini C, Bauden M, Zhou Q, Hu D, Andersson R: The Hippo Signaling 
Pathway in Pancreatic Cancer. Anticancer Res 2019, 39(7):3317-3321. 
 
 
Oncogenes	YAP/TAZ	role	in	the	Hippo	signaling	pathway	in	pancreatic	cancer	
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Figure 4.2 The Hippo signal pathway in pancreatic cancer. Upstream signaling in the 
hippo pathway results in the phosphorylation of YAP, and its co-activator (TAZ). When 
YAP and TAZ are held in the cytoplasm, they are degraded to prevent their entry into the 
nucleus. In the nucleus, they bind to TEADs 1-4, and are responsible for the upregulation of 
genes involved in proliferation. However, aberrant signaling of the hippo pathway in 
pancreatic cancer is associated with cancer promoting factors. 
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VGLL1 has been shown to interact with TEAD4 in a manner similar to that of 
YAP/TAZ, resulting in the upregulation of the proliferation-promoting gene IGFBP5 and 
facilitating anchorage-independent cell growth (Figure 4.3) [163]. These studies suggest that 
VGLL1 may promote cancer progression directly, which would increase its potential value as 
a therapeutic target. Although the VGLL1 transcript loss observed in Patient MP015 could 
argue against a role as an essential driver gene, the degree of tumor evolution documented in 
this patient’s cancer progression was exceptionally high [158].  
The function of VGLL1 in healthy tissues, points to a critical role in placenta cell 
proliferation. In addition, (Figure 3.5), high VGLL1 expression in pancreatic and basal-like 
breast cancer patients is associated with a poorer prognosis [154]. Furthermore, cancer cells 
are known to co-opt the Hippo signaling pathway and upregulate YAP/TAZ to increase 
tumor- promoting factors. Based on the current evidence on YAP/TAZ within the Hippo 
signaling pathway and the connection with VGLL1, we hypothesized that VGLL1 may play 
a role in cancer tumorigenesis through promoting proliferation, migration, and/or invasion. In 
the following section, we will discuss how we aimed to test our hypothesis and demonstrate 
why VGLL1 is a promising therapeutic target in pancreatic cancer. 
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Figure	4.3 VGLL1 and YAP/TAZ share similar interaction with TEADs in the hippo 
pathway. 
	
	
Figure	used	with	premission	from	author:	
Pobbati	AV,	Chan	SW,	Lee	I,	Song	H,	Hong	W:	Structural	and	functional	similarity	between	the	
Vgll1-TEAD	and	the	YAP-TEAD	complexes.	Structure	2012,	20(7):1135-1140.	
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Figure	4.3 VGLL1 and YAP/TAZ share similar interaction with TEADs in the hippo 
pathway. The well-established YAP/TAZ oncogenes bind to TEADs in cancer cells to 
activate cancer-promoting factors. VGLL1 appears to also bind to the TEADs and perform a 
similar function, by upregulating genes that are also known to promote cancer progression 
such as; VEGF-A and the anchorage-independent growth factor IGFBP-5.  
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	 	
	
142	
	
4.3.) VGLL1 overexpression leads to increased proliferation, migration, and invasion of 
cancer cells in vitro. 
To access any potential changes that VGLL1 expression may induce in tumors, we 
first generated two VGLL1-overexpressing lines. VGLL1 lenti-viral vectors were used to 
transduce tumor cells that did not express VGLL1, as assessed by western blot. We utilized 
the cell lines PANC1, a pancreatic tumor cell line, and H1975, a lung cancer line. The cells 
were transduced to express VGLL1, and VGLL1 protein expression was validated by 
Western blot analysis, as shown in Figure 4.4A.  PANC10.05, a naturally-expressing 
VGLL1-postive cell line was used as a positive control. We next generated transient 
knockdowns of  the VGLL1 transduced H1975 lung cancer cells. To create the transient 
knockdowns, we used esiRNA vectors (MISSION® esiRNA Cat. #EHU042561); this 
allowed for increased chances of knocking down VGLL1 expression to a greater degree than 
standard siRNA. Mission esiRNA works by targeting the same mRNA sequence with 
multiple siRNAs, and thus guarantees at least a 70% knockdown efficiency. We confirmed 
reduced VGLL1 expression in the knockdown cells by Western blot analysis (Figure 4.4B). 
Following the validation of the VGLL1- transduced cell lines, we proceeded to 
observe morphological changes in the cells. Evident growth and phenotypic differences were 
found in the H1975 cell lines post-VGLL1 transduction. Cells were plated and analyzed 
using microcopy at 24, 48, 72, and 96 hours. As shown in Figure 4.5 at the 72hr mark, 
VGLL1 over-expressing H1975 lung tumor cells had formed multiple clusters despite 
growing in a 2D culture (Figure 4.5C). The clusters resembled similar growth patterns to 3D 
spherical organoid cell culture, similar to the MP015 organoid cell line from which the 
VGLL1 peptide was derived. 
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This may indicate  ability of VGLL1 to induce growth in an anchorage-independent 
matter [186, 187], which is also an indication of metastatic potential [186]. The colonies 
were alive; some were attached to the flask and some were floating in the supernatant. 
However, once they were collected and re-plated, all cells survived and continued  to grow 
and expand in a similar matter. Knocking down VGLL1 in the overexpressed lung cancer 
cells returned the cells to a similar phenotype of parental H1975 cells and GFP-transduced 
control cells (Figure 4.5D).  
Simultaneously we counted the H1975 tumor cells to assess proliferation counts. On 
day one, we plated 30,000 cells in triplicates, and the cells were observed at 24, 48, 72, and 
96hr mark, using a Nexcelom cellometer (Figure 4.6). As expected, the VGLL1 
overexpressed cells proliferated faster than the WT VGLL1-negative cells, P >0.001 (Figure 
4.6). Additionally, the VGLL1 knockdown cells grew similarly to the parental line (Figure 
4.6). We failed to reject our hypothesis that VGLL1 plays a role in tumor cell proliferation. 
The upregulation of VGLL1 may be used by tumor cells to promote growth.  
The few papers that have been published on VGLL1 hint at its potential role in tumor 
cell migration and invasion. Migration and invasion differ from one another, in that 
migration refers only to a cell’s ability to fill-in an area or move from one point to another 
[188]. Invasion defers from migration; in that it looks at the ability to migrate coupled with 
the cell’s ability to move past an extracellular matrix. We first accessed the ability of PANC1 
VGLL1 overexpressing cells migration in comparison to VGLL1-negative cells, by 
performing a wound healing assay. Cells were plated at 500,000 cells per well in triplicates 
in the Cytoselet wound healing plates (Cell biolabs, Cat.#CBA-120).  Each well contained a 
pre-placed insert that creates 0.9mm gap for measuring migratory cells. After 24hrs the insert 
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was removed and migration of the cells were observed for an additional 48hrs. At the 48hr 
mark, VGLL1 over-expressing cells had nearly filled in the entire wound area (Figure 4.7A). 
While WT and GFP-transduced control PANC1 cells, had migrated at a significantly slower 
rate (Figure 4.7A). By analyzing multiple images and comparing the wound-healing area, we 
concluded that the VGLL1-expressing cells migrated significantly faster than the other two 
cell lines, P>0.0001 (Figure 4.7B).  We also noted again in this assay that VGLL1-
transduced cells formed clusters that grew in three dimensions.  
Based on the survival data of pancreatic and basal-like breast cancer patients (Figure 
3.5 and 3.6), we reasoned that VGLL1 may have an effect on the aggressiveness of tumors in 
vivo [154]. We next set out to determine if VGLL1 expression increased the invasiveness of 
tumor cells in vitro. The invasiveness of a cell is determined by its ability to degrade and 
migrate through an extracellular membrane barrier. We utilized PANC1 VGLL1-
overexpressing cells, along with WT parental, and GFP transduced  controls cells. The 
CHEMICON cell invasion kit by Millipore was used to conduct this assay. An invasion 
chamber, containing a thin layer of an extracellular membrane (ECM) was inserted into a 
well. The cells were placed inside of the invasion chamber in serum-free media, and RPMI 
with 10% FBS was placed into the well below. The tumor cells were plated at 50,000 cells 
per well and allowed to migrate for 48hrs. At the 24 and 48hr mark, cells attached to the 
ECM were harvested. The invasive cells were stained and dried, following the collection of 
the chambers, and counted by microscopy. The assay was performed in triplicates, a mean of 
all invasive cells was derived from total cell counts. As shown, PANC1 VGLL1-expressing 
cells had significantly more invasive cells than VGLL1 non-expressing PANC1 parental cells 
(Figure 4.8A). Quantification of the total cells counts indicated that  VGLL1-expressing 
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cells demonstrated >10X the number of invasive cells after 48hrs, P >0.0001 (Figure 4.8B). 
This data provides strong evidence that VGLL1 expression can drive tumor cell invasiveness, 
and is consistent with the poor survival noted in patients with tumors demonstrating high 
VGLL1 expression. 
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VGLL1	protein	expression	in	a	pancreatic	
and	lung	cancer	line	
FIGURE 4.4. Transduction of VGLL1 in two negatively expressing cell 
lines. 
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Figure 4.4. Transduction of VGLL1 in two negatively expressing cell lines. VGLL1 was 
transduced in the pancreatic line, (A) PANC1 and the lung cancer line, H1975 (B).  The lung 
cancer line, H1975 was also knocked down by esiRNA following overexpression. 
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Figure 4.5. VGLL1 induces morphology changes following transduction 
in lung cancer cells.  
H1975	tumor	cell	lines	
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Figure 4.5. VGLL1 induces morphology changes following transduction in lung cancer 
cells. VGLL1 was transduced into H1975 lung cancer cells. At 72hrs, the cells were analyzed 
by microscopy for morphological changes. (Shown 10X left, 100X right) No differences 
were seen in PANC1 (A) Parental, (B) GFP after 72 hrs. Following transduction, (C) 
VGLL1-expressing cells formed spherical colonies that were not observed in the un-
transduced WT cell line. (D) Knockdown cells retained the same phenotype of the parental 
and GFP cells. 
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Proliferation	of	H195	tumor	cells	
Figure 4.6 Total cell counts of H1975 tumor cells.  
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Figure 4.6 Total cell counts of H1975 tumor cells. Cells were played in 
triplicates on day 1 at 30,000 cells per well. Each day, the cells were 
harvested, counted, and the totals were then averaged. Total cell counts were 
averaged and compared to day 1 (24hrs) for fold change in GraphPad. Data is 
shown as mean ± STD *P <0.05 , **P<0.01. 
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The	effect	of	VGLL1-overxpression	on		
PANC1	tumor	cells	migration	
Figure 4.7 VGLL1 increases migration of PANC1 tumor cells following 
transduction. 
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Figure 4.7 VGLL1 increases migration of PANC1 tumor cells following 
transduction. 
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Figure 4.7. VGLL1 increases migration of PANC1 tumor cells following transduction. 
(A, B) Representative image of the effect of VGLL1-overpexressing on the migration of 
PANC1 tumor cells.  Cells were plated in triplicates, and the area of the wound was 
measured for all the fields of each well using Image J. Total migrated cell counts were 
averaged in GraphPad. Data is shown as mean ± STD *P<0.05 , *** P< 0.001. 
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	 Figure 4.8. VGLL1 Transwell Invasion Assay.	
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FIGURE 4.8. PANC1 Transwell Invasion Assay. (A) Representative microscopic images of cells that 
migrated through the extra cellular matrix layer and clung to the bottom of the polycarbonate membrane. 
Cells were plated on the same day for two time points, 24hr and 48hr at 50,000 cells per well. The cells 
were harvested at each time point. (B) The quantification of the invasive cells was performed using image 
J for total migrated cells. Data from triplicates was averaged and analyzed by graphpad prism. Data is 
shown as mean ± STD ****P<0.0001. 
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4.4.) Discussion 
The Hippo signaling pathway plays a critical role in cancer progression through the 
oncogenes YAP and TAZ [178]. These two genes are co-transcriptional activators to the 
TEADs within the Hippo signaling pathway. Cancers highjack this pathway and induce the 
expression of YAP/TAZ to promote downstream target gene expression that promotes the 
hallmarks of cancer [185]. These include genes involved in tumor cell proliferation, 
migration, and invasion [169, 179, 185]. Since VGLL1 shares considerable homology to 
YAP/TAZ, this prompted us to explore VGLL1’s potential role in also increasing these 
‘hallmarks of cancers”.  
Through these studies, we were able to show that VGLL1 expression induces distinct 
morphological changes in pancreatic and lung tumor cells. The overexpression of VGLL1 
induced both PANC1 and H1975 cells to exhibit aberrant growth patterns, in which cells 
grew in multiple small clusters with some attached and others detached from the culture 
plates. Despite being grown in 2D culture in traditional monolayers, the cells appeared to 
acquire the ability grow more like that of 3D culture cells. This differed significantly from 
what was observed in the parental and GFP-transduced tumor cells that retained normal 
growth patterns. This strongly suggests that VGLL1 does have a direct impact on tumor cell 
growth. VGLL1 can induce anchorage-independent growth in VGLL1-transduced prostate 
tumor cells [163, 189]. This pattern of growth is a marker used to assess the metastatic 
potential of tumors [186]. Malignant cells often acquire the ability to detach and continue to 
grow and proliferate without being attached to a substrate. The next step would be to perform 
a soft agar colony formation assay with VGLL1- transduced tumor cells. This assay 
specifically analyzes anchorage-independent growth and will help confirm this phenotype.  
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We showed that VGLL1 expression increased the proliferation rate of H1975 lung 
tumor cells (Figure 4.6). Furthermore, VGLL1 expression also significantly increased the 
migration and invasion of PANC1 pancreatic tumor cells (Figure 4.8). These results suggest 
that VGLL1 can induce many of the same phenotypes in tumor cells as YAP/TAZ. 
Additionally, according to the TCGA, VGLL1 and TAZ are not co-expressed, but rather are 
mutually exclusive. Since, VGLL1 is thought to compete for binding to the TEADs with 
YAP/TAZ, it may play a redundant role in cancer.  However, more studies remain to be done 
to elucidate its role in cancer progression.  
Moving beyond in vitro studies into mouse models will be necessary to answer many 
remaining questions. Mouse VGLL1 overexpression and knockdown plasmids have been 
prepared to transduce mouse cell lines. It is also important to note that mouse and human 
VGLL1 do not totally share overlapping symmetry; they only share 41% homology. The 
mouse VGLL1 protein sequence is also nearly twice as long the human VGLL1.  Therefore, 
there may be some differences in their functions, but this still needs to be determined. Since 
human placenta has the highest expression of VGLL1, it will be important to determine if 
this is also the case in mice. Mouse placenta mRNA sequencing is planned to explore this 
question. Additionally, RNA sequencing and Nanostring of a panel of human and mouse 
tumor cell lines will be useful to determine what signaling pathways or genes may be 
associated with VGLL1 expression. The studies in this dissertation have revealed some 
intriguing results in vitro, but in vivo studies could substantially increase the significance of 
these results. Based on the current findings, VGLL1 appears to play a role in cancer 
progression similar to YAP/TAZ, but could also perform additional tasks that have yet to be 
discovered.  
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CHAPTER V: 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
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V. Overall Conclusions and Future Studies. 
5.1 Overall Conclusions 
One of the major objectives of this dissertation was to identify a shared, targetable 
TAA to facilitate the development of a novel T cell based immunotherapy.  By utilizing HLA 
immunoprecipitation, peptide elution, and MS-based tumor antigen discovery, we were 
successful in achieving our goal. Through our initial efforts working with ovarian tumor 
specimens, we identified a HLA-B*07:02-restricted MUC16-derived peptide.  This MUC16-
derived peptide, TPPGTQRSL, appeared to have great potential as a TAA (Table 2.3). 
However, after attempts at T cell generation failed, we opted to stop pursuing this antigen as 
a target (Figure 2.9 and 2.10).  
T cell tolerance may be the reason why our efforts to generate T cells against MUC16 
were unsuccessful. MUC16 is one of the largest surface glycoproteins at >22,000 amino 
acids. It also contains many tandem repeats that are shared among other surface mucins. 
Since MUC16 is primarily found in low abundance in female reproductive tissues, we 
utilized healthy male donor PBMCs in our attempts to try to isolate MUC16-specific T cells. 
While we were unsuccessful at expanding MUC16-specific T cells from this one  male 
donor, it is possible that other donors would have given a different outcome. There is 
evidence that MUC16 peptides can be immunogenic, as shown in other studies [107]. 
However, cross-reactivity with other self-antigens may still be an issue should MUC16- 
specific T cell generation be successful in the future.  
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Since we also were working with pancreatic cancer tumor specimens simultaneously, 
we identified the novel epitope, LSELETPGKY, derived from the cancer placenta antigen 
VGLL1 (Table 3.1). This peptide was found in a pancreatic-patient derived tumor organoid 
cell line. This added to the novelty of our finding, because there are only a few established 
cancer-placenta antigens previously discovered [165]. Thus, VGLL1 is likely the first cancer 
placenta antigen to be targeted clinically with T cell based immunotherapies.  
VGLL1 peptide specific CTLs were generated from this same patient, and expanded 
to >20 billion cells. This demonstrated that VGLL1 was immunogenic, further adding to its 
potential as TAA target. These cells were administered to the patient as a treatment, but by 
the time they received the T cells, the patient had lost tumor VGLL1 transcript expression 
(Figure 3.13). Despite the patient’s loss of the VGLL1 gene target, this infusion showed that 
there were no adverse effects or toxic effects from receiving the VGLL1-specific T cells. 
 Further work revealed VGLL1 to be a promising shared TAA not just for pancreatic, 
but for multiple other cancers; including ovarian, bladder, lung, and breast cancers. We 
showed that VGLL1-specific T cells show minimal recognition of primary cell lines, with the 
exception of mammary cells. This may be the one area of caution for treatment of patients. 
However, the infused patient did not experience any apparent toxic off target reactivites, so 
this may not be a serious issue as our in vitro killing assay would suggest. Since, VGLL1 has 
now been approved for an MD Anderson clinical trial of ETC we will know soon if toxicities 
are seen in treated other patients. 
The identification of VGLL1 also presented many additional questions pertaining to 
its role in cancer progression. As previously stated, very few studies have been published on 
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VGLL1 and most did not directly assess its function in cancer development. VGLL1 has 
minimal expression in normal tissues, with the exception of the placenta where it is 
expressed at over 200 TPMs on average (Figure 4.1) VGLL1 is expressed in 
cytothrophoblasts within the placenta, these cells are the responsible for implanting the 
placenta in the uterus, and forming the critical blood supply from the mother to the fetus 
[171].  Due to the function and nature of cytothrophoblasts, we speculate that VGLL1 may 
be involved in driving its high proliferation and invasive behavior.  
Additionally, VGLL1 shares a similar binding motif to the well-characterized 
oncogenes YAP/TAZ, within the Hippo signaling pathway [169, 187]. This signaling 
pathway is the key regulator of organ size and development [184]. It appears that VGLL1 
may compete for binding to the TEAD family of genes with YAP/TAZ. Once either of these 
genes bind to the TEADs, they act as co-transcriptional activators, inducing the expression of 
different cancer-promoting genes [174]. YAP/TAZ are linked to pancreatic, lung, and breast 
cancer progression by promoting factors that increase EMT transition, proliferation, 
chemoresistance, and immune evasion [169, 185, 190].  
VGLL1 was specifically shown to upregulate anchorage-independent proliferation in 
a prostate cancer cell line following transduction [187]. Anchorage-independent growth is a 
key trait in cells transitioning into a metastatic state [186].  TAZ  induces the migration, 
invasion, and tumorigenesis of breast cancer cells through the Hippo pathway [182]. Since 
VGLL1 may share similar characteristics to YAP/TAZ in the Hippo pathway, this led us  to 
explore if VGLL1 expression could also induce a similar phenotype in pancreatic tumor 
cells. VGLL1 transduction indeed increased proliferation, migration, and invasion of 
pancreatic tumor cells (Figure 4.5-4.8). These provide evidence supporting the idea that 
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VGLL1 may play a role in driving cancer progression as well. We hypothesize that VGLL1 
may be important for tumor cell proliferation and invasion early in tumorigenesis.  This 
hypothesis is partly based on the observation of the pancreatic patient losing VGLL1 
expression overtime, despite having high expression early on. We believe that VGLL1 may 
not be an essential driver in cancer, but rather an initiator, or potentially a stress dependent 
response. We observed in that cells that became close to 100% confluent in culture 
experienced a period of “crashing”, and slow recovery after being re-plated. However, after 
that initial period they proliferated quickly again and became confluent. We think this may 
be due to VGLL1 expression being turned on only when it is needed for migration, but when 
cells begin to come in close contact, VGLL1 is downregulated to halt the growth of the 
tumor cells. This mechanism could be used by tumors to slow growth when space and 
resources become scarce, such as in low-nutrient environments. VGLL1-signaling in the 
Hippo pathway may be downregulated and other pathways may be upregulated to support the 
tumor during this time. The tumor microenvironment of pancreatic cancer controls abundant 
stroma that contribute to fibrosis, which limits oxygen and nutrients for the tumor cells [191]. 
Pancreatic tumor cells turn on scavenging pathways in order to survive these environments, 
and continue to thrive in times of low nutrients [191]. However, this is just one of the many 
possible explanations of  for the aberrant changes in VGLL1 expressing-tumors in vitro. 
Performing experiments with mouse tumor models is the ideal next direction for our VGLL1 
studies, in order to determine in vivo relevance.  
5.2 Future Directions 
To better understand the role of VGLL1 in disease progression, studying rare cancers 
that arise during gestation may help shed light on VGLL1’s role in tumorigenesis. 
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Gestational trophoblastic disease (GTD) is a rare group of tumors that develop in the placenta 
during early pregnancy. These tumors includes invasive moles, choriocarcinoma (CCA), and 
the more aggressive placental site trophoblastic tumor and epithelioid trophoblastic tumor 
(PSTT/ETT) [192]. These tumors occur in due to abnormal growth of trophoblasts. 
Currently, the mechanism behind the development of these caners at a molecular level 
remains unknown. Since we know that VGLL1 is highly overexpressed in trophoblasts, and 
is likely important for the invasive nature of trophoblasts during the development of placenta, 
there may be a connection between VGLL1 expression and GTD development during 
pregnancy. 
One of the ways we could access the role of VGLL1 in GTD is to examine a cohort of 
GTD patient tumor samples, and perform IHC staining to compare VGLL1 expression in 
normal placenta vs. GTD patient tumors. We could determine if VGLL1 is expressed more in 
GTD patient’s vs normal tissue donors. This would aid in determining if VGLL1 is important 
for the initiation of GTD tumors. By identifying if VGLL1 is highly overexpressed in these 
tumors, we could next determine what is causing the aberrant expression of VGLL1 in the 
trophoblasts. We could achieve this by accessing if mutations within the Hippo signaling 
pathway may be connected to the activation of VGLL1 signaling by looking at upstream 
signaling partners of VGLL1 within in the Hippo pathway.  
By performing genetic analysis on tumor samples, this may provide more in-depth 
insight into the mutational changes occurring that lead to what may be the constitutive 
activation Hippo signaling pathway mediated by VGLL1 upregulation. We could utilize RT-
PCR or Real-Time PCR to look for mutations at the RNA level. We could also access 
differences at the DNA level, by performing micro array. In addition to looking specifically 
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at VGLL1, we could also determine if other major players may be involved in the initiation 
of GTD, such as YAP/TAZ, within in the Hippo signaling pathway. 
Once targets have been identified, we could confirm their involvement with small molecule 
inhibitors of the Hippo signaling pathway to determine if proliferation of GTD tumor cells is 
reduced. By performing these set of studies we may be the first to show how GTD tumors 
arise and provide alternative forms of treatments for patients that fail to response to the front 
line therapy.  
One approach to analyze proliferation, and migration, invasion would be to utilize an 
immunodeficent mouse model in which human VGLL1-expressing and non VGLL1-
expressing tumors can be grown, monitoring the tumor site and metastasis over time. It will 
require more extensive studies to assess the role of VGLL1 in immune evasion that we 
cannot be explored in immunodeficent mice. Development of a mouse model to study 
VGLL1 function in vivo is currently in the very early stages. We have the plasmids 
constructed to create mouse VGLL1 overexpressing and knockdown cell lines. We have 3 
different human pancreatic tumor lines that have been transduced to overexpress VGLL1, 
and human placenta cells that we plan to use for comparison of pathways associated with 
VGLL1 in primary tissues. Additionally, we are planning to explore pathways and gene 
expression that may be connected to mouse VGLL1 expression by utilizing nanostring and 
RNA sequencing.  Nanostring and RNA sequencing will provide insights into the molecular 
mechanisms controlling VGLL1 expression or what is being controlled by VGLL1 
expression. There is still so much to left to learn about VGLL1, and we still very much in the 
early stages of uncovering the significance of VGLL1 in cancer progression.  
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Together, this dissertation has unveiled a novel shared TAA that shows great promise 
as a therapeutic target for multiple cancers. VGLL1 is relatively uncharacterized in cancer, 
but its homology to YAP/TAZ makes a compelling case to continue studies of this gene. If 
the role of VGLL1 in in cancer progression cancer can be determined, it may open the door 
to additional upstream or downstream therapeutic targets of VGLL1.With much to be 
discovered, it is a very exciting point in research on VGLL1. We hope work will continue to 
build on the foundation outlined in this dissertation, and in turn affect cancer patient’s lives 
for the better in the future. 
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CHAPTER VI: 
 
MATERIALS AND METHODS 
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Cell Lines.  Human cancer cell lines demonstrating VGLL1 mRNA expression were 
identified using the Cancer Cell Line Encyclopedia (CCLE) microarray-based gene 
expression analysis.  HLA-A*0101-expressing cancer cell lines PANC10.05, CAPAN-1 
OAW28, HT1197, HT1376, BXPC3, UBCL-1, and primary cell lines were obtained from 
commercial sources (ATCC and Sigma-Aldrich). Two VGLL1 negative cells lines were also 
collected, the pancreatic cell line PANC1 and the lung cancer line H1975 was obtained from 
(ATCC). The patient-derived organoid cell line MP015-Org (hMIA2D) was generated by the 
Tuveson lab at Cold Spring Harbor Labs as previously described (29599906). The patient-
derived organoid cell line MP081-Org was generated by the Maitra lab from tumor tissue 
derived from a wedge biopsy. The gastric cancer cell lines GT-5 and MKN74 were a kind 
gift from Dr. Lee Ellis. WM793, MKN74, PANC1005, GT-5, and OAW28 cells were 
cultured in RPMI 1640 medium (GIBCO), containing 10% fetal bovine serum, 1% penicillin-
streptomycin (Pen-Strep) (Cellgrow), and 1% Insulin-Transferrin-Seleum-A (GIBCO). BT20 
and bladder cell lines were cultured in equal parts DMEM F12K and MEM Alpha, with FBS, 
Pen-Strep, and 1% sodium pyruvate (GIBCO). All other cell lines were cultured in RPMI 
1640, FBS, and Penn-strep, with the addition of HEPES (GIBCO) and Glutamax (GIBCO).  
 
Lentiviral Transductions. Some HLA-A*0101-negative tumor cell lines that naturally 
expressed VGLL1 protein were transduced with a lentiviral gene transfer vector to express 
HLA-A*0101 driven by the human PGK promoter, as previously described [193].  Ectopic 
cell surface expression of A*0101 was assessed by staining with anti-human HLA-A1-biotin 
and streptavidin-FITC (US Biological) and measuring fluorescence using a FACScanto II 
flow cytometer (BD Biosciences). Tumor cells expressing physiological and comparable 
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levels of surface HLA-A*0101 were isolated by cell sorting and used in subsequent 
experiments. To conduct proliferation and invasion assays WT cell lines with no VGLL1 
expression were compared to lenti-viral overexpressed cell lines. For cell lines with no 
VGLL1 expression, the origene plasmid was used to generate a lentivirus (RC600200L1V, 
Origene). WT VGLL1 negative cell lines were transduced to express VGLL1 and protein 
expression was validated by western blot analysis. 
 
VGLL1 Protein Expression.  VGLL1 protein expression was confirmed in all cell lines by 
Western blot analysis. Cell lysates from tumor and primary cell lines were prepared and 
protein content normalized using the BCA method (Thermo-Fisher).  Using standard Western 
blot techniques, cell lysates were run by polyacrylamide gel electrophoresis, transferred, and 
membranes probed with VGLL1-specific rabbit polyclonal antibody (TA322329, OriGene). 
VGLL1 protein was visualized using an enzyme-linked anti-rabbit mAb with the Scientific 
Pierce Fast Western Blot Kit, according to the manufacturer’s instructions. 
 
Peptide Identification, Selection and Validation. Patient-derived laparoscopic wedge 
biopsies, xenografts (PDX), or cell lines were lysed using Triton X-100 and cell lysates 
incubated overnight at 4oC with 1µg of pan-HLA-ABC specific mAb W6/32 for every 10 mg 
of protein. Protein A/G Ultralink resin beads were used to immunoprecipate HLA class I 
molecules and HLA-bound peptides were then eluted with 0.1M acetic acid. HLA-A,B,C 
isolation was confirmed by Western blot analysis, then HLA-positive elutes were analyzed 
by tandem mass spectrometry (MS/MS). HLA class I protein recovery was semi-
quantitatively assessed by rating Western blot band intensity on a scale from 0 (not 
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detectable) to 4 (highest intensity). Tumor-associated HLA-bound peptides were injected 
onto HPLC system (Dionex 3000 RSLC), and separated by reverse-phase chromatography in 
0.1% formic acid water-acetonitrile on 1.8µm C18 (Agilent Technologies) in the MS/MS 
discovery phase. Peptides were analyzed on an Orbitrap Elite mass spectrometer (Thermo-
Fisher) using data-dependent acquisition. To analyze the acquired MS/MS spectra, the 
Mascot algorithm was utilized to search the spectra against the SwissProt complete human 
protein database (updated 9/2018), which provided potential matches to conventionally 
annotated peptides.  
Individual peptide matches underwent quality assessment by reference to multiple 
orthogonal parameters, including Mascot Ion score, MS1 measured differential to the 
calculated peptide mass (delta mass), and predicted binding to the patient’s HLA allotypes as 
determined by high-resolution genetic sequencing and the NetMHC and NetMHCpan 
algorithms [100],[101].  High-confidence peptide matches were analyzed by BLAST 
searches to identify all potential source genes, which were then cross-referenced to RNAseq 
data derived from individual tumor samples to provide further validation of peptide identity 
(validation requiring a minimum source gene expression of 0.3 transcripts per million, TPM). 
Eluted TAA peptides were screened for safety as potential CTL targets by applying 
sequential RNA transcript expression filters to eliminate peptides most likely to elicit 
autoimmune toxicities due to normal tissue expression (GTex Portal RNAseq data, 
http://cancergenome.nih.gov/). Excluding testis and placenta, source gene transcript 
expression of 30 TPM maximum was allowed in non-essential tissues (listed in Table S2), 10 
TPM in “caution” tissues, 3 TPM in “hazard” tissues and 1 TPM in highly essential “danger” 
tissues (such as heart and brain). Putative TAA genes were also screened for expression and 
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prevalence in different cancer types through analysis of TCGA RNAseq data 
(http://cancergenome.nih.gov/). In selected cases, targeted-MS/MS analysis was performed to 
confirm TAA peptide identity. For these analyses, retention-time windows for 13C/15N 
isotope-labeled synthetic peptide standards were pre-determined by MS analysis of the 
synthetic peptides, then targeted methods for searching TAA peptides were constructed using 
mass windows of 3 Da around each m/z. 
 
Gene Expression Analysis and Patient Survival.  Whole transcriptome sequencing 
(RNAseq) analysis was performed on RNA derived from all PDAC tumor specimens, 
xenografts, and organoid cell lines using the Illumina TruSeq Stranded Total RNA kit with 
Ribo-Zero Gold with approximately 200 million paired-end reads for each tumor RNA 
sample (Avera Institute for Human Genetics). Gene expression profiles of VGLL1 and other 
cancer placenta antigens were determined by compiling RNAseq data derived from normal 
human primary tissues (GTex Portal) and tumor tissues (TCGA). Kaplan-Meier curves were 
generated from survival data of TCGA cancer patients when stratified by tumor VGLL1 
transcript expression. 
Isolation and expansion of antigen-specific CD8 T cells.  We generated three antigen-
specific T cells. A MART-1 HLA-A*0201 restricted peptide was used as our control antigen. 
The MUC16 B0702-restricted peptide TPGGTRQSL, and the VGLL1 peptide HLA-A*0101 
restricted peptide LSELETPGKY were both our experimental test antigens.  Antigen–
specific CTLs were generated as previously described [194], [195], [196]. To generate T 
cells against both the A2-restricted MART-1 derived peptide, and MUC16 B7-restricted 
peptide, we begin with the same healthy donor. This donor was both HLA-A2*0201 and 
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HLA-B*0702 positive. We isolated PBMCs from this healthy-donor. PBMCs derived from 
this this donor were stimulated in separate wells by MART-1 peptide and B7-restricted 
MUC16 peptide. After the stimulation, cultured cells were stained with either an MART-
1/HLA*0201 or MUC16/HLA-B*0702-PE conjugated custom tetramer. (Fred Hutchinson 
Cancer Research Center), washed and then stained with APC-conjugated CD8 antibody. 
Cells were washed and analyzed by flow cytometry (LSRFortessa X-20 Analyzer). CD8 and 
tetramer double-positive cells were sorted by ARIA II and the VGLL1-specific CD8 T cells 
were expanded using the Rapid Expansion Protocol (REP) with PBMC and LCL feeder cells, 
as previously described.(16081794). 
To generate VGLL1-specific T cells HLA-A*0101 positive patient- or healthy donor-
derived PBMCs were stimulated twice by autologous dendritic cells (DCs) pulsed with the 
VGLL1231-240 peptide LSELETPGKY. Six days after the second DC stimulation, cultured 
cells were stained with VGLL1231-240 peptide/HLA-A*0101–PE-conjugated custom tetramer 
(Fred Hutchinson Cancer Research Center), washed and then stained with APC-conjugated 
CD8 antibody. Cells were washed and analyzed by flow cytometry (LSRFortessa X-20 
Analyzer). CD8 and tetramer double-positive cells were sorted by ARIA II and the VGLL1-
specific CD8 T cells were expanded using the Rapid Expansion Protocol (REP) with PBMC 
and LCL feeder cells, as previously described.(16081794) The TCR Vβ repertoire of 
expanded CD8 T cells was assessed using the IOTest Beta Mark TCR-Vβ Repertoire kit. 
Cytotoxic T cell assays. Antitumor killing by VGLL1-specific CD8+ T cells was assessed 
using a standard chromium-51 (51Cr) release assay. Target cells were labeled with 100µL of 
51Cr for 1 hour, then washed and plated at 2,000 target cells per well in triplicate. VGLL1-
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specific CD8+ T cells were incubated with target cells at various effector-to-target (E:T) cell 
ratios for four hours. After the incubation period, supernatant was collected from the wells 
and 51Cr was measured with a gamma radiation counter. The percentage of specific target 
cell lysis was calculated, correcting for background 51Cr release and relative to a maximum 
51Cr release as measured by Triton X-100 lysed target cells. 
 
esiRNA Knockdown. VGLL1 knockdown cells were generated using MISSION 
esiRNA (Cat. #EHU042561, Millipore). H1975-VGLL1 expressing cells were transfected 
with esiRNA two months after VGLL1 transduction. The cells were re-assessed by western 
blot analysis for VGLL1 over-expression prior to knockdown. 48hrs post-transfection, the 
cells were checked by western blot analysis for knockdown. Once knockdown was 
confirmed, they were immediately used in assays. 
 
Proliferation Assays. H1975 VGLL1-transduced, GFP, and parental cells were plated in 
triplicates at 30,000 cells per well. Each line was plated in wells marked 0hr, 24hr, 72hr, and 
96hrs. At each time point the cells were collected and counted by Nexcelom Cellometer. 
Cells counts were averaged at each time and the data was analyzed using graph pad prism. 
 
Wound Healing Assay. The CytoSelect™ Wound Healing Kit from Millipore (Cat.# CBA-
120) was used to perform  the wound healing assay. The kit contained well inserts that 
created 0.9mm gaps. PANC1 VGLL1 transduced, GFP, and parental cell lines were plated at 
and collected after 24hrs. 500,000 cells were collected in media and 500 µL of the cell 
suspension was added to each well insert in triplicates. The cells were incubated overnight 
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and sterile forceps were used to remove the well inserts. The media was changed and the 
cells visualized under the microscope. We monitored the cells for an additional 48 hrs., 
taking images each day. Migration was assessed by the visualization and quantification of the 
wound at multiple areas within the well for each day. Data was analyzed by Image J and 
Graphpad Prism.  
Transwell Invasion assays.  Invasiveness of VGLL1 transduced, GFP, and parental 
PANC1 cells was accessed with the use of the QCM ECMatrix Cell Invasion Assay 
(Millipore Sigma, Cat. # ECM550). Cells were plated in triplicate in two time points, 
24hr and 48hr at 50,000 cells per well in chamber inserts containing a thin-monolayer 
of extracellular membrane. RPMI with 10% FBS media was added to the well below. 
The cells were then left to incubate at their respective time points and were harvested 
at each point. The cells were stained with crystal violet stain following washing a 
cleaning of the ECM insert chamber. Cells attached to the ECM after washing were 
counted by first visualizing under a microscope and photos were analyzed by Image J. 
Cell count data was then further analyzed in Grahpad Prism.  
Statistical analysis.  Data analysis was performed using GraphPad Prism version 7.03. 
Normally distributed data were analyzed using parametric tests (ANOVA or unpaired t test). 
Kaplan-Meier survival curves were analyzed by log-rank tests. Test differences were 
considered statistically significant if P<0.05. 
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